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ABSTRACT: A series of imidazo[1,5-a]quinoline derivatives
was designed and synthesized as central benzodiazepine
receptor (CBR) ligands. Most of the compounds showed
high CBR affinity with Ki values within the submicromolar and
subnanomolar ranges with interesting modulations in their
structure−affinity relationships. In particular, fluoroderivative
7w (Ki = 0.44 nM) resulted in the most potent ligand among
the imidazo[1,5-a]quinoline derivatives described so far.
Overall, these observations confirmed the assumption
concerning the presence of a large though apparently saturable
lipophilic pocket in the CBR binding site region interacting
with positions 4 and 5 of the imidazo[1,5-a]quinoline nucleus.
The in vivo biological characterization revealed that compounds 7a,c,d,l,m,q,r,w show anxiolytic and antiamnestic activities
without the unpleasant myorelaxant side effects of the classical 1,4-BDZ. Furthermore, the effect of 7l,q,r, and 8i in lowering
lactate dehydrogenase (LDH) release induced by ischemia-like conditions in rat brain slices suggested neuroprotective properties
for these imidazo[1,5-a]quinoline derivatives.
■ INTRODUCTION
The neurotransmitting action of γ-aminobutyric acid (GABA)
at the GABAA chloride channel complex modulates the
excitability of many central nervous system (CNS) pathways.1
GABAA receptors are ligand-gated ion channels (LGICs)
belonging to the Cys-loop superfamily, the same as nicotinic
acetylcholine, glycine, zinc-activated, and 5-HT3 receptors. Cys-
loop receptors are characterized by the assembly of five
subunits, which form pentameric arrangements around a central
ion-conducting pore and are the targets of many drugs.1 The
function of GABAA receptors is regulated, in addition to the
agonist binding site, by allosteric sites interacting with a large
variety of agents.2 Positive modulators of the GABAA receptors,
such as the classical 1,4-benzodiazepine (BDZ) diazepam (1,
Figure 1), are therapeutically employed as sedatives, muscle
relaxants, anxiolytics, and anticonvulsants, whereas negative
GABAA modulators (i.e., BDZ inverse agonists) show
anxiogenic and convulsant effects.3−6 Finally, neutral modu-
lators, such as the imidazo[1,5-a][1,4]benzodiazepines fluma-
zenil (2), bind to GABAA receptor but have no intrinsic activity
at the central benzodiazepine receptor (CBR). Thus, flumazenil
is recognized to antagonize the activity of both positive and
negative GABAA modulators acting via the CBR.
Because positive modulators show amnesic effects in animal
and man,7−10 negative modulators were assumed to possess
procognitive properties.11,12 However, the use of nonselective
CBR inverse agonists in the treatment of neurological disorders
associated with cognitive impairment was limited by their
anxiogenic and convulsant effects.13
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A large number of subunits (i.e., α1−6, β1−4, γ1−4, δ, ε, π, θ,
and ρ1−3) has been cloned and sequenced, but most of GABAA
receptors are composed of α, β, and γ-subunits arranged in a
2:2:1 stoichiometry.14 In fact, among the multitude of
theoretically possible combinations deriving from the coassem-
bly of the subunits, only the receptor subtypes containing a γ2
or γ3
15 subunit in conjunction with α1, α2, α3, or α5 appear to
bind BDZ ligands with significant affinity. The CBR binding
domain is assumed to be located at the interface between α and
γ subunits, which contribute to the building of the active site
with their amino acid residues.16 Investigations based on
molecular genetic or pharmacological approaches suggested
that α1 subunit is involved in the sedative and muscle relaxant
effects of the nonselective BDZ agonists, whereas α2 or α3 can
be responsible for the anxiolytic and anticonvulsant effects.17−19
The recognition of the pharmacological and physiological roles
of α subunits in GABAA receptor subtype functions has
stimulated new interest in this receptor system as the target for
the development of drugs showing fewer side effects with
respect to the classical benzodiazepines (e.g., nonsedating
anxiolytics) or possessing different indications with respect to
the classical benzodiazepines (e.g., analgesics, cognition-
enhancing drugs).20−27 A number of compounds has been
developed that show GABAA receptor subtype selectivity.
20 In
particular, subtype-selective GABAA receptor ligands were
obtained either by selective binding (i.e., by forming a
receptor−ligand complex with a particular receptor subtype)
or by selective efficacy (i.e., by eliciting a biological response
after binding to the receptor). These two properties are both
important in defining the potency profile.20
Very interestingly, the full range of intrinsic efficacies
observed in the series of imidazo[1,5-a][1,4]benzodiazepine
derivatives 3 was modulated in a rather subtle manner by the
substitution pattern.28,29 A similar behavior was observed when
the seven-membered ring of the benzodiazepine system was
contracted as in the series of imidazo[1,5-a]quinoxaline
derivatives 4, which were developed in the 1990s in Upjohn
laboratories.30−35 The large body of work performed by the
Upjohn researchers led to the proposal of the existence of a
second low affinity-binding site on GABAA receptors, the
occupancy of which (at high drug concentrations) may reverse
the positive allosteric action on CBR and potentially minimize
dependence and abuse liability.36
Among the large number of imidazo[1,5-a]quinoxaline
derivatives developed, compound 4a (see Figure 1) was
shown to induce a negative allosteric modulation via this
second low affinity binding site.36 On the basis of the huge
amount of structure−activity relationship (SAR) data on
imidazo[1,5-a]quinoxaline derivatives 4, the structure of 4a
was easily translated into the imidazo[1,5-a]quinoline one of 5
(see Figure 1), which was considered as a drug candidate for
the treatment of anxiety, but its development was discontinued
for safety reason (i.e., centrally mediated respiratory depression
having lethal effects).37 The identification of 5 as a candidate
for development studies was apparently performed among a
limited set of imidazo[1,5-a]quinoline derivatives so that the
available SAR data on this class of CBR ligands is limited. In
general, the analysis of the available SAR data suggested that
bulky substituents are tolerated by CBR binding site when they
are located in the ligand region corresponding to positions 4
and 5 of the imidazo[1,5-a]quinoline nucleus consistently with
the results obtained with 5-HT3 receptor ligands based on
quinoline structure 6.38,39 Similarly, these bulky substituents
appeared to play a role in modulating the intrinsic efficacy.39
These observations, together with the structural analogies
existing between GABAA and 5-HT3 receptors, led us to apply
the approach used in studying 5-HT3 receptors to the
characterization of CBR binding features by means of the
design, synthesis, and pharmacological characterization of
imidazo[1,5-a]quinoline derivatives 7, 8, and 9 in comparison
with reference imidazo[1,5-a]quinoxalines 10 (Figure 2).
■ RESULTS AND DISCUSSION
Chemistry. The preparation of target imidazo[1,5-a]-
quinoline derivatives was performed by imidazo-annulation of
Figure 1. Structure of reference compounds.
Figure 2. Design of imidazo[1,5-a]quinoline 7−9 starting from piperazinylquinoline 5-HT3 receptor ligands 6.
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suitable 2-chloroquinoline derivatives 11−24 with ethyl
isocyanoacetate or tert-butyl isocyanoacetate in the presence
of potassium tert-butoxide providing 7a−i,k−m,o−y (Scheme
1) in the yields reported in Table 1. The structure of 7p,s,t was
confirmed by crystallographic studies (see Supporting
Information).
The starting 2-chloroquinoline derivatives were either
compounds known (see Table 1) or prepared by standard
methodology.38,40 On the other hand, target propargylamide
derivative 7n was synthesized from tert-butyl ester 7k via acid 7j
(Scheme 2).
Acyl chloride 2538 was reacted with potassium tert-butoxide
in dry THF to obtain ester 16, which was used in the above-
described imidazo-annulation with ethyl isocyanoacetate,
affording diester 7k. The cleavage of the tert-butyl ester moiety
of the latter with formic acid gave the expected carboxylic acid
7j, which was in turn transformed via acyl chloride into the
expected propargylamide 7n.
The target imidazo[1,5-a]quinoline derivatives bearing
substituents in position 7 of the tricyclic nucleus was carried
out as outlined in Scheme 3.
The appropriately substituted quinolinone derivatives
26a,b41 were converted into the corresponding 2-chloroquino-
line derivatives 27a,b by reaction with phosphorus oxychloride.
The amidation of the carboxyl group of 27a,b afforded the
expected amides 22−24, which were used in the above-
described imidazo-annulation with ethyl isocyanoacetate or tert-
butyl isocyanoacetate to obtain target compounds 7w,x,y.
Bromoderivative 7y was then used in Sonogashira coupling
Scheme 1. Imidazo-Annulation of 2-Chloroquinoline
Derivatives 11−24 to Target Imidazo[1,5-a]quinoline
Derivatives 7a−i,k−m,o−ya
aReagents: (i) CNCH2COOC2H5 or CNCH2COOC(CH3)3, tert-
BuOK, DMF. Substituents: see Table 1.
Table 1. Preparation of Target Compounds 7a−i,k−m,o−y
target X Y Z R starting source yield (%)
7a OC2H5 N(CH3)2 H H 11 Experimental Section 35
7b OC(CH3)3 N(CH3)2 H H 11 Experimental Section 59
7c OC2H5 N(CH3)n-C4H9 H H 12 Experimental Section 10
7d OC(CH3)3 N(CH3)n-C4H9 H H 12 Experimental Section 17
7e OC2H5 N(n-C3H7)2 H H 13 see ref38 72
7f OC(CH3)3 N(n-C3H7)2 H H 13 see ref38 48
7g OC2H5 N(CH3)CH2C6H5 H H 14 see ref38 56
7h OC(CH3)3 N(CH3)CH2C6H5 H H 14 see ref38 36
7i OC2H5 N(C2H4)2NCH3 H H 15 see ref40 25
7k OC2H5 OC(CH3)3 H CH3 16 Scheme 2 94
7l OC2H5 N(n-C3H7)2 H CH3 17 see ref38 60
7m OC(CH3)3 N(n-C3H7)2 H CH3 17 see ref38 46
7o OC2H5 N(CH3)CH2C6H5 H CH3 18 see ref38 26
7p OC(CH3)3 N(CH3)CH2C6H5 H CH3 18 see ref38 46
7q OC2H5 N(n-C3H7)2 H C2H5 19 see ref38 27
7r OC(CH3)3 N(n-C3H7)2 H C2H5 19 see ref38 15
7s OC2H5 N(C2H5)2 H n-C3H7 20 see ref38 21
7t OC(CH3)3 N(C2H5)2 H n-C3H7 20 see ref38 55
7u OC2H5 N(n-C3H7)2 H n-C3H7 21 see ref38 5
7v OC(CH3)3 N(n-C3H7)2 H n-C3H7 21 see ref38 4
7w OC2H5 N(n-C3H7)2 F H 22 Scheme 3 21
7x OC2H5 N(CH3)CH2C6H5 F H 23 Scheme 3 15
7y OC2H5 N(CH3)CH2C6H5 Br H 24 Scheme 3 62
Scheme 2. Synthesis of Target Derivatives 7j,k,na
aReagents: (i) tert-BuOK, THF; (ii) CNCH2COOC2H5, tert-BuOK,
DMF; (iii) HCOOH; (iv) SOCl2; (v) N-methylpropargylamine,
CH2Cl2.
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reaction with trimethylsilylacetylene to afford 7aa, which was
promptly desilylated with into 7z.
Most of the target imidazo[1,5-a]quinoline derivatives
bearing the phenyl substituents in position 5 of the tricyclic
nucleus was accomplished as sketched in Scheme 4, while the
preparation of compound 8i is described in Scheme 5.
Imidazo-annulation of suitable 2-chloro-4-phenylquinoline
derivatives 28−3142 with ethyl isocyanoacetate or tert-butyl
isocyanoacetate in the presence of potassium tert-butoxide gave
target derivatives 8a,b,e,g,h. The cleavage of the tert-butyl ester
moiety of esters 8b,e with formic acid gave carboxylic acid
derivatives 32 and 33, which were converted via 2,3,5,6-
tetrafluorophenyl esters into the desired amides 8c,d,f.
Lithium aluminum hydride reduction of ester 30 gave
hydroxymethylquinoline derivative 34, which was first
protected by reaction with tert-butyldimethylsilyl chloride
(TBDMSCl) and then submitted to the conditions of the
imidazo-annulation with ethyl isocyanoacetate or tert-butyl
isocyanoacetate to afford imidazo[1,5-a]quinoline 36, which
was promptly desilylated into target 8i.
Finally, the imidazo-annulation was applied also to
chloroderivative 3743 to obtain tetracyclic target compound 9
and to quinoxalinone derivatives 38 and 39.31 However, these
latter intermediates required a more complex reaction pathway
consisting of a first activation step with diethyl chlorophosphate
followed by a second step of annulation with ethyl
isocyanoacetate or tert-butyl isocyanoacetate in the presence
of potassium tert-butoxide to obtain reference imidazo[1,5-
a]quinoxaline 10a−d (Scheme 6).31 The structure of 10a−c
was confirmed by crystallographic studies (see Supporting
Information).
In Vitro Binding. The affinity of the imidazo[1,5-
a]quinoline derivatives 7a−aa, 8a−g, 9, and 10a−c for CBR
in bovine cortical membranes was measured by means of
competition experiments against the radiolabeled antagonist
[3H]flumazenil. The results of the binding studies are expressed
as Ki values in Tables 2 and 3. The in vitro efficacy of the target
compounds was tentatively estimated by measuring the GABA
ratio (GR, expressed as a ratio of Ki without GABA/Ki with
GABA), which is considered reasonably predictive of the
pharmacological profile of a CBR ligand.44−47 Usually, this
value approximates 2 for full agonists and 1 for antagonists,
while partial agonists show intermediate values between 1 and
2; finally, GABA ratio values below 1 are typical of inverse
agonists.
Scheme 3. Synthesis of the Target Imidazo[1,5-a]quinoline
Derivatives Bearing Substituents in Position 7a
aReagents: (i) POCl3; (ii) SOCl2; (iii) amine, CH2Cl2, TEA; (iv)
CNCH2COOC2H5, tert-BuOK, DMF; (v) trimethylsilylacetylene,
Pd(PPh3)2(AcO)2, TEA; (vi) Bu4NF, THF. Substituents: Z = F in
22, 23, 26a, and 27a; Z = Br in 24, 26b, and 27b; Y = N(n-C3H7)2 in
7w and 22; Y = N(CH3)CH2C6H5 in 7x,y, 23 and 24.
Scheme 4. Synthesis of the Target Imidazo[1,5-a]quinoline
Derivatives Bearing the Phenyl Substituents in Position 5a
aReagents: (i) CNCH2COOC2H5 or CNCH2COOC(CH3)3, tert-
BuOK, DMF; (ii) HCOOH; (iii) 2,3,5,6-tetrafluorophenol, EDC,
Na2CO3, H2O, CH3CN; (iv) HN(CH3)2 for 8c (or HN(CH3)-
CH2C6H5 for 8d,f), THF. Substituents: R = H in 8a−d, 28, and 32; R
= CH3 in 8e,f, 29, and 33; R = COOC2H5 in 8g and 30; R =
CH2COOC2H5 in 8h and 31; X = OC2H5 in 8a,g,h; X = OC(CH3)3 in
8b,e; X = N(CH3)2 in 8c; X = N(CH3)CH2C6H5 in 8d,f.
Scheme 5. Synthesis of the Imidazo[1,5-a]quinoline
Derivative 8ia
aReagents: (i) LiAlH4, THF; (ii) TBDMSCl, imidazole, CH2Cl2; (iii)
CNCH2COOC2H5, tert-BuOK, DMF; (iv) Bu4NF, THF.
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Most of the compounds were found to inhibit the specific
binding of radiolabeled flumazenil at the bovine CBR with Ki
values within the submicromolar and the subnanomolar ranges
with the full range of the intrinsic efficacy as predicted by
GABA ratio values (0.52−1.6).
The analysis of the structure−activity relationships confirmed
the importance of the substituents in positions 4 and 5 of the
imidazo[1,5-a]quinoline scaffold in modulating both the CBR
affinity and the intrinsic efficacy (Figure 3). The most potent
CBR ligands were obtained in the series of imidazo[1,5-
a]quinoline derivatives bearing a N,N-dipropylaminocarbonyl
group at position 5 of the tricyclic nucleus. However, also other
lipophilic substituents are tolerated in the binding site region
interacting with position 5 of the imidazo[1,5-a]quinolone,
namely N,N-dimethylaminocarbonyl, N-methybutylaminocar-
bonyl, N-methypropargylaminocarbonyl, N-methybenzylamino-
carbonyl, tert-butoxycarbonyl, and phenyl groups (Figure 3).
However, the tolerance to large substituents in position 5
appeared to be conditioned by the presence of additional steric
bulk in position 4 of the tricyclic scaffold (Figure 4).
Scheme 6. Synthesis of Target Compounds 9 and 10a−da
aReagents: (i) CNCH2COOC2H5, tert-BuOK, DMF; (ii) tert-BuOK,
(C2H5O)2POCl, THF; (iii) CNCH2COOC2H5 or CNCH2COOC-
(CH3)3, tert-BuOK, THF. Substituents: X = H in 10a,b and 38; X = F
in 10c,d and 39; R = C2H5 in 10a,c; R = C(CH3)3 in 10b,d.
Table 2. Inhibition of [3H]Flumazenil Specific Binding to CBR in Cortical Membranes and GABA Ratio Values of Compounds
7a−aa
compd X Y Z R Ki ± SEM
a (nM) GABA ratiob
7a OC2H5 N(CH3)2 H H 8.2 ± 2.3 1.3
7b OC(CH3)3 N(CH3)2 H H 11 ± 1.9 1.6
7c OC2H5 N(CH3)n-C4H9 H H 1.9 ± 0.7 0.76
7d OC(CH3)3 N(CH3)n-C4H9 H H 1.8 ± 0.5 0.62
7e OC2H5 N(n-C3H7)2 H H 0.91 ± 0.01 1.0
7f OC(CH3)3 N(n-C3H7)2 H H 1.2 ± 0.5 1.1
7g OC2H5 N(CH3)CH2C6H5 H H 20 ± 2.9 0.52
7h OC(CH3)3 N(CH3)CH2C6H5 H H 14 ± 0.35 0.98
7i OC2H5 N(C2H4)2NCH3 H H 55 ± 4.5 1.0
7j OC2H5 OH H CH3 105 ± 26 1.2
7k OC2H5 OC(CH3)3 H CH3 1.0 ± 0.37 1.4
7l OC2H5 N(n-C3H7)2 H CH3 1.5 ± 0.08 1.3
7m OC(CH3)3 N(n-C3H7)2 H CH3 1.0 ± 0.03 1.1
7n OC2H5 N(CH3)CH2CCH H CH3 1.2 ± 0.02 1.0
7o OC2H5 N(CH3)CH2C6H5 H CH3 6.5 ± 0.4 1.1
7p OC(CH3)3 N(CH3)CH2C6H5 H CH3 2.6 ± 0.1 1.0
7q OC2H5 N(n-C3H7)2 H C2H5 2.5 ± 0.3 1.5
7r OC(CH3)3 N(n-C3H7)2 H C2H5 5.6 ± 0.4 1.4
7s OC2H5 N(C2H5)2 H n-C3H7 169 ± 14 0.9
7t OC(CH3)3 N(C2H5)2 H n-C3H7 2870 ± 250 1.1
7u OC2H5 N(n-C3H7)2 H n-C3H7 34 ± 4.5 1.1
7v OC(CH3)3 N(n-C3H7)2 H n-C3H7 1437 ± 120 1.0
7w OC2H5 N(n-C3H7)2 F H 0.44 ± 0.2 0.8
7x OC2H5 N(CH3)CH2C6H5 F H 5.7 ± 2.6 0.8
7y OC2H5 N(CH3)CH2C6H5 Br H 24 ± 1.7
c 0.90c
7z OC2H5 N(CH3)CH2C6H5 CCH H 161 ± 24
c 0.95c
7aa OC2H5 N(CH3)CH2C6H5 CCSi(CH3)3 H 510 ± 48
c 0.99c
flunitrazepam 5.2 ± 0.2 1.68
flumazenil 1.9 ± 0.09 1.03
aKi values are means ± SEM of three independent determinations in bovine cortical membranes.
bGABA ratio = (Ki without GABA/Ki with 50 μM
GABA). cThe values were obtained in rat cortical membranes.
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In fact, in the dipropylamido subseries (Figure 4), the
increase of the alkyl side chain length led to a stepwise decrease
in CBR affinity with a rapid acceleration in propyl derivatives
7u,v. This result can be rationalized in terms of interactions
between the ester group and the alkyl moiety in position 4 but
also with by assuming that the lipophilic pocket can be
saturated as previously observed in 5-HT3 receptors.
38
On the other hand, in the imidazo[1,5-a]quinoline subseries
bearing a phenyl group in position 5 (Figure 4), the effects of
the substituents in position 4 were highly variable and appeared
to depend on the stereoelectronic features of the substituent
itself.
In general, small substituents such as H, CH3, and CH2OH
are tolerated better than the bulkier carbethoxy group of
compound 8g, but the spacing of the ester group by a
methylene bridge as in 8h restored nanomolar CBR affinity,
suggesting the involvement of specific interactions.
Table 3. Inhibition of [3H]Flumazenil Specific Binding to CBR in Cortical Membranes and GABA Ratio Values of Compounds
8a−i, 9, and 10a−d
bovine human
compd X R Ki ± SEM
a (nM) GABA ratiob Ki ± SEM
a (nM) GABA ratiob
8a OC2H5 H 42 ± 9.6 0.9
8b OC(CH3)3 H 55 ± 32 0.8
8c N(CH3)2 H 3515 ± 360 1.44
8d N(CH3)CH2C6H5 H 449 ± 10 0.92
8e OC(CH3)3 CH3 10 ± 2.8 1.0
8f N(CH3)CH2C6H5 CH3 >1000
c
8g OC2H5 COOC2H5 2193 ± 633 0.66
8h OC2H5 CH2COOC2H5 3.8 ± 2.1 0.72
8i OC2H5 CH2OH 1.8 ± 0.1 1.18 2.0 ± 0.2
9 18 ± 3.5 1.3
10a H C2H5 25 ± 9.6 0.90 33 ± 4.2
10bd H C(CH3)3 7.3 ± 1.5 0.98 7.7 ± 1.3 1.04
10c F C2H5 2.2 ± 0.42 0.75 2.7 ± 0.3 0.95
10d F C(CH3)3 1.0 ± 0.46 1.0 2.0 ± 0.3 1.0
flunitrazepam 5.2 ± 0.2 1.68 6.4 ± 0.5 1.61
flumazenil 1.9 ± 0.09 1.03 2.0 ± 0.08 1.02
aKi values are means ± SEM of three independent determinations.
bGABA ratio = (Ki without GABA/Ki with 50 μM GABA).
c19% displacement at
1000 nM. dSee ref 31.
Figure 3. SAR in imidazo[1,5-a]quinoline derivatives 7a−i and 7j−p. Effects of the lipophilic substituents in position 5.
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As already observed in related CBR ligands, the presence of
small atoms such as H or F in position 7 is required for
nanomolar CBR affinity, whereas the presence of the bulkier
bromine atom produces a significant drop in CBR affinity that
became dramatic (i.e., almost 2 orders of magnitude) when
alkyne substituents are present in this position as in compounds
7z−aa (Figure 5).
It is noteworthy that the beneficial effect of the fluorine
substituent was less evident in imidazo[1,5-a]quinoline
derivatives 7w,x than in imidazo[1,5-a]quinoxaline derivatives
10c,d. However, by virtue of its subnanomolar CBR affinity (Ki
= 0.44 nM), fluoroderivative 7w resulted more potent than the
corresponding imidazo[1,5-a]quinoxaline derivative 10c and is
the most potent ligand among the imidazo[1,5-a]quinoline
derivatives described so far.
Finally, the replacement of ester groups in position 3 of
imidazo[1,5-a]quinoline derivatives 8a,b,e with the amide ones
of 8c,d,f (Figure 6) was deleterious from the point of view of
the interaction with CBR binding site producing low affinity
ligands.
In Vitro Efficacy in 36Cl− Uptake Assay in Rat
Cerebrocortical Synaptoneurosomes. The comparison of
the GABA ratio values showed a rather complex pattern in the
structure−activity relationships of imidazo[1,5-a]quinoline
derivatives 7a−aa, 8a−g, 9, and 10a−c. In general, the
agonist-like properties appeared to be linked to the presence
of relatively small substituents (i.e., 7a,b), whereas the presence
of large lipophilic substituents appeared to be associated with
antagonist-like features. However, ligands showing apparently
different intrinsic efficacy were present in the same subseries
without evidencing a clear trend. This could be due both to the
complexity of the interaction and to possible experimental
errors.
Thus, the predictive capability of GABA ratio values was
evaluated in the limited set of reference imidazo[1,5-a]-
quinoxaline derivatives 10b−d by means of a more direct
measure of in vitro efficacy consisting in 36Cl− uptake assay in
Figure 4. SAR in imidazo[1,5-a]quinoline derivatives 7e,f,l,m,q,r,u,v and 8a,b,e,g,h,i. Effects of the alkyl substituents in position 4.
Figure 5. SAR in imidazo[1,5-a]quinolines 7e,g,w,x,y,z,aa and
reference imidazo[1,5-a]quinoxalines 10a−d. Effects of the substitu-
ents in position 7.
Figure 6. SAR in imidazo[1,5-a]quinolines 8a−f. Effects of the
substituents in position 3.
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rat cerebrocortical synaptoneurosomes.48,49 The synaptic
chloride conductance effected by GABA activating the
GABAA receptor complex is modulated by ligands acting at
the CBR. In particular, agonists increase the current,
antagonists are ineffective, and inverse agonists decrease the
ion flow. The results shown in Figure 7 suggested that reference
10b behaved as a CBR antagonist in agreement with its GABA
ratio values (0.98−1.04) and with the data described in the
literature.31
Compound 10d (GABA ratio = 1.0) showed a very slight
increase of 36Cl− influx, behaving as a partial agonist
characterized by a very low intrinsic efficacy. On the other
hand, an even slight decrease in the ion flow was observed with
compound 10c (GABA ratio in bovine CBR = 0.75, in human
CBR = 0.95), which could be therefore classified either as a
partial inverse agonist showing a very low intrinsic efficacy or as
an antagonist. No massive 36Cl− influx was promoted by these
reference compounds in agreement with their antagonist-like or
partial inverse agonist properties as predicted by GABA ratio
values. On the whole, these apparent discrepancies emphasized
the importance of a suitable biological characterization of the
newly synthesized CBR ligands in order to appreciate their
pharmacological profile.
In Vitro Efficacy in Excytotoxic-Mediate Injury. The
disruptions in GABA signaling is involved in many acute and
chronic neurodegenerative disorders such as temporal lobe
epilepsy, Parkinson’s disease (PD), Huntington’s disease (HD),
and brain ischemia. The GABAergic system is indeed
indispensable to keep the balance between the excitation and
the inhibition required for normal neuronal function. An
imbalance between these systems contribute to excitotoxicity
and neuronal cell death. Consequently, modulation of the
GABAergic system can successfully reverse excitotoxic-induced
injury in disease models, suggesting that therapeutic strategies
targeting the GABAergic system could be effective in treating
neurodegenerative disorders.50−52 Positive modulators of the
GABAA receptors, such as diazepam and the partial agonist
imidazo[1,5-a]quinoline derivative 5, have proven to show
neuroprotective properties in different models of excytotoxic-
mediated injury.53−57 Therefore, imidazo[1,5-a]quinoline de-
rivatives 7l,q,r, and 8i were selected on the basis of their Ki and
GABA ratio values (i.e., nanomolar CBR affinity and partial
agonist profile) and tested for their potential neuroprotective
Figure 7. 36Cl− uptake measured in rat cerebrocortical synaptoneur-
osomes for compounds 10b (magenta), 10c (blue), 10d (cyan),
flunitrazepam (empty circles), flumazenil (empty diamonds), and ethyl
β-carboline (empty squares).
Figure 8. Effects of 7l,q,r, 8i, and diazepam on oxygen−glucose deprivation and reoxygenation (OGD/R)-induced release of LDH of rat brain
cortical slices. Slices were incubated in artificial cerebrospinal fluid (ACSF) for 120 min (control conditions, CTRL) or subjected for 30 min to
oxygen/glucose deprivation followed by 90 min incubation in normally oxygenated ACSF (reperfusion). Increasing concentrations of the
compounds (0.1−100 μM) were added to ACSF during the 90 min reperfusion phase. Data are means ± SEM of at least four different experiments.
°°°P < 0.01 vs CTRL; *P < 0.05, **P < 0.01, ***P < 0.001 vs OGD/R (ANOVA followed by Dunnet post-test).
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activity. Rat cortical brain slices were subjected to excitotoxic-
mediated damage (i.e., oxygen-glucose deprivation and
reoxygenation, OGD/R) and neuronal injury/neuroprotection
was assessed by measuring the release of lactate dehydrogenase
(LDH). All drug molecules were added during reperfusion and
their effects were compared to those exerted by diazepam. The
results demonstrated that diazepam exerted neuroprotective
effects according to a “U-shaped”, hormetic-like, concentra-
tion−response curve, with an efficacy window of 0.5−10 μM
(Figure 8). In this range, the maximum recovery in LDH
release was 55.9%, which was observed at both 1 and 5 μM
concentrations (Table 4).
The hormetic effect of diazepam was already observed54 and
might be explained by considering that elevated diazepam levels
at the synaptic cleft might cause an excessive activation of
GABAA receptors, which increases the overload of Cl
− and
causes GABAA desensitization, thus resulting in depolarization
and neuron damages.58,59 In the same way, imidazo[1,5-
a]quinoline derivatives 7l,q,r, and 8i showed neuroprotective
properties. All the compounds, in fact, reduced OGD/R-
induced LDH release in a hormetic-like fashion although with
different efficacy windows. In particular, 8i and 7r were the
most interesting compounds (Figure 8) because they exerted
their effects in a wider concentration range than diazepam (i.e.,
1−25 μM 8i or 1−50 μM 7r), but the maximum recovery in
LDH release was lower (39.5% and 44.4%, respectively, at 5
μM, see Table 4). Also, 7l,q reverted the release of the
endocellular enzyme caused by the ischemia-like conditions but
the maximum effect was observed at 50 μM concentration and
the recovery was 44%. Taken together, these results suggests
that 7l,q,r and 8i could behave as partial agonists at GABAA
receptors in the present experimental model because they
exhibited lower efficacy than the positive GABAA modulator
diazepam.
In Vivo Efficacy. The newly synthesized compounds
7a,c,d,l,m,p,q,r,w were evaluated in mice as modulators of
central nervous system functionalities after per os admin-
istration. In particular, four pharmacological actions were taken
into consideration. The light−dark box test was used to
ascertain the potential anxiolytic effect, while the rota-rod test
measured the myorelaxant effect, the hole-board test was
performed to assess the effects on mouse spontaneous motility
and explorative activity, and the passive avoidance test was
finally used to evaluate the mouse learning and memory
impairment.
The anxiolytic effect of the molecules is shown in Figure 9.
The light−dark box test is based on the innate aversion of
rodents to the brightly lit and open areas and on the
spontaneous novelty-induced exploratory behavior, allowing
the evaluation of potential anxiolytic compounds. All
compounds, with the exception of 7p, increased the time
spent in the light box after dosing at 10 mg kg−1. Compounds
7d (167.2 ± 6.5 s), 7r (172.5 ± 7.2 s), and 7w (181.4 ± 8.3 s)
were the most effective showing a comparable effect with
diazepam (1 mg kg−1 subcutaneously) (Figure 9). Compound
7d presented a dose-dependent anxiolytic effect, which was
significant starting from 3 mg kg−1 (144.8 ± 6.3 s; data not
shown). A similar potency was showed by compound 7l, which
was active starting from 3 mg kg−1 (153.4 ± 6.1 s; data not
shown) peaking at 10 mg kg−1 (Figure 9). Compound 7m was
the most potent because it was effective at 1 mg kg−1 (Figure
9), whereas 7p was ineffective when administered at 1 and 10
mg kg−1 (Figure 9), but by increasing the dose to 30 mg kg−1
the time was enhanced up to 139.2 ± 5.1 s (data not shown).
To validate the behavioral measurements, possible neuro-
logical or muscular side effects of the tested compounds were
excluded by the hole-board and the rota-rod tests. All the
compounds (10 mg kg−1) did not alter the neurological and
muscular abilities of the mice as evaluated by the hole-board
test 30 min after treatment. The number of movements (motor
activity) and the number of inspections (exploratory activity)
were comparable to vehicle-treated animals (Figure 10).
Similarly, no negative effects on motor coordination emerged
in the rota-rod test (Figure 11). The treated animals showed a
progressive ability to maintain the balance on a rotating rod.
The nootropic effects were assessed in the passive avoidance
test measuring the prevention of scopolamine-induced amnesia.
The muscarinic antagonist drastically reduced the time spent in
the light box of the apparatus during the retention session (44.8
± 8.1 s vs 101.4 ± 7.0 s of vehicle-treated animals; second
experimental day) highlighting a lack of memory of the
punishment received in the dark box (Figure 12). Compounds
7c,d,l,m,p,q,r,w (10 mg kg−1) were able to significantly prevent
Table 4. Effects of 7l,q,r, 8i, and Diazepam on Oxygen−
Glucose Deprivation and Reoxygenation (OGD/R)-Induced
Release of LDH of Rat Brain Cortical Slicesa
compd efficacy windowb (μM) ECc (μM) recoveryd (%)
7l 5−50 50 44.0 ± 8.5*
7q 5−100 50 44.3 ± 4.8***
7r 1−50 5 44.4 ± 2.4***
8i 1−25 5 39.5 ± 5.6***
1 0.5−10 1 55.9 ± 7.1***
5 55.9 ± 5.9***
aRat cortical brain slices were subjected to oxygen-glucose deprivation
and reoxygenation and neuronal injury/neuroprotection was assessed
by measuring the release of lactate dehydrogenase (LDH). All drugs
were added during reperfusion. bThe efficacy windows represent the
range of concentrations at which a significant reduction of OGD and
reperfusion-induced LDH release was observed. cEC (effective
concentration) is the μM concentration at which the highest reduction
was observed. dThe recovery value represents the % of reversion
exerted at EC concentration; 100% was taken as the return to basal
values (CTRL). Recovery data are reported as mean ± SEM and the
comparison between values was performed by using ANOVA followed
by Dunnet post-hoc test.*P < 0.05, ***P < 0.001 vs OGD/R.
Figure 9. Light−dark box test. Anxiolytic activity. The new
compounds were administered per os, and diazepam (1 mg kg−1)
was administered subcutaneously. All treatments were performed 30
min before the test. Each value represents the mean ± SEM of at least
10 mice. **P < 0.01 in comparison to vehicle-treated mice.
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scopolamine-induced amnesia (Figure 12). Compound 7w was
the most effective (99.6 ± 9.2 s), and both 7r and 7w were
effective also at 1 mg kg−1. Compound 7d was effective starting
from 3 mg kg−1 (73.5 ± 8.8 s; data not shown). Ten mg kg−1
compound 7p was not effective in the passive avoidance test
(Figure 12). However, the dose of 30 mg kg−1 increased the
time of the retention session up to 77.9 ± 7.8 s (data not
shown), while 7a was ineffective (Figure 12).
■ CONCLUSION
The structural analogies existing between GABAA and 5-HT3
receptors suggested the application of the approach we used in
studying 5-HT3 receptors to the characterization of CBR
interaction features. Thus, a series of imidazo[1,5-a]quinoline
derivatives related to 5 (a previously described drug candidate
for the treatment of anxiety) was designed, synthesized, and
biologically characterized in comparison with reference
imidazo[1,5-a]quinoxalines 10a−d. Most of the newly
synthesized compounds showed high CBR affinity with Ki
values within the submicromolar and the subnanomolar ranges
and interesting SAR trends, which suggested the existence of a
large though apparently saturable lipophilic pocket in the CBR
binding site region interacting with positions 4 and 5. From
another perspective, this result could be interpreted as the
evidence of a certain degree of conformational freedom of the
amino acid residues interacting with the substituents in
positions 4 and 5 of the imidazo[1,5-a]quinoline nucleus.
Thus, this promising evidence paves the way to the application
of our approach to the study of the 5-HT3 receptor to the
characterization of the interaction of CBR with divalent and
more in general multivalent ligands.60 Fluoroderivative 7w (Ki
= 0.44 nM) resulted the most potent ligand and despite its
inverse agonist−antagonist profile suggested by its GABA ratio
value of 0.8, acted as an agonist in the light−dark box test, the
classical animal model of anxiety, and was devoid of the
undesired myorelaxant side effects. In addition, compound 7w
(at 1 mg kg−1) was found to significantly prevent scopolamine-
induced amnesia, showing the best efficacy among the
compounds evaluated in the in vivo studies (7a,c,d,l,m,p,q,r).
Furthermore, imidazo[1,5-a]quinoline derivatives 7l,q,r, and 8i
showed neuroprotective properties because they reduced LDH
release induced by ischemia-like condition in an hormetic-like
fashion although with different efficacy windows.
■ EXPERIMENTAL SECTION
Chemistry. All chemicals used were of reagent grade. Yields refer
to purified products and are not optimized. Melting points were
determined in open capillaries on a Gallenkamp apparatus and are
uncorrected. Merck silica gel 60 (230−400 mesh) was used for column
chromatography. Merck TLC plates, silica gel 60 F254 were used for
TLC. NMR spectra were recorded by means of either a Bruker AC
200 or a Bruker DRX 400 AVANCE spectrometers in the indicated
solvents (TMS as internal standard); the values of the chemical shifts
are expressed in ppm and the coupling constants (J) in Hz.
The purity of compounds 7a−aa, 8a−i, 9, and 10a−d was assessed
by RP-HPLC and was found to be higher than 95%. An Agilent 1100
series system equipped with a Phenomenex C18 (3.9 mm × 150 mm,
10 μm) column or a Zorbax Eclipse XBD-C8 (4.6 mm × 150 mm, 5
μm) column was used in the HPLC analysis with acetonitrile−
methanol−water (10:20:70) or (10:40:50) or (10:50:40) or
(10:70:20) as the mobile phases at a flow rate of 2.0 mL/min. UV
detection was achieved at 254 nm. Mass spectra were recorded on
either a Thermo LCQ-Deca or an Agilent 1100 LC/MSD.
General Procedure for the Synthesis of Target Imidazo[1,5-
a]quinoline Derivatives 7a−i,k−m,o−y. A mixture of the suitable 2-
chloroquinoline derivative (11−24, 1 equiv) was cooled at 0−5 °C in
dry DMF (typically, 10 mL for 1 mmol) under argon and then treated
with the suitable isocyanoacetate (3 equiv) and potassium tert-
butoxide (3 equiv). The resulting mixture was stirred for 30 min at 0−
5 °C, then allowed to stir at room temperature for 1 h, and finally
heated at 80 °C for 1−20 h (following the reaction progress by TLC).
Figure 10. Hole-board test. Effects on neurological and muscular
abilities. All compounds were administered per os 30 min before the
test. Each value represents the mean ± SEM of at least 10 mice.
Figure 11. Rota-rod test. Effects on motor coordination. All
compounds were administered per os 30 min before the test. Each
value represents the mean ± SEM of at least 10 mice.
Figure 12. Passive avoidance test. Effects on learning and memory. All
compounds were administered per os 30 min before the test.
Scopolamine (1.5 mg kg−1 intraperitoneally) was administered
immediately after the punishment. The time recorded during the
retention session is reported. Each value represents the mean ± SEM
of at least 10 mice. *P < 0.05 and **P < 0.01 in comparison to vehicle-
treated mice.
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After cooling to room temperature, acetic acid (typically, 1.0 mL for 1
mmol) was added and the mixture was stirred for additional 20 min
and then poured onto crushed ice. The precipitate was collected by
filtration, washed with water, dissolved into chloroform, and the
organic layer washed with brine, dried over Na2SO4, and concentrated
under reduced pressure. The residue was purified by flash-
chromatography with the suitable eluent to afford the expected
imidazo[1,5-a]quinoline derivative (7a−i,k−m,o−y), which after
recrystallization from the suitable solvent gave an analytical sample.
Ethyl 5-(Dimethylcarbamoyl)imidazo[1,5-a]quinoline-3-carboxy-
late (7a). The title compound was obtained as a white solid from 11
according to the above general procedure and purified by flash
chromatography with ethyl acetate as the eluent (yield 35%). An
analytical sample was obtained by recrystallization from ethyl acetate−
chloroform by slow evaporation (white crystals, mp 209−210 °C). 1H
NMR (400 MHz, CDCl3): δ 1.45 (t, J = 7.1, 3H), 2.96 (s, 3H), 3.23
(s, 3H), 4.46 (q, J = 7.1, 2H), 7.52 (t, J = 7.6, 1H), 7.63−7.77 (m, 2H),
8.03 (s, 1H), 8.09 (d, J = 8.3, 1H), 8.70 (s, 1H). 13C NMR (100 MHz,
CDCl3): δ 14.5, 35.0, 38.9, 60.8, 115.3, 121.2, 125.6, 126.9, 127.0,
128.4, 130.4, 130.6, 131.2, 132.7, 163.0, 168.0. MS (ESI) m/z calcd for
C17H17N3O3Na [M + Na]
+, 334.1; found, 334.2.
tert-Butyl 5-(Dimethylcarbamoyl)imidazo[1,5-a]quinoline-3-car-
boxylate (7b). This compound was prepared from 11 according to the
above general procedure and purified by flash chromatography with
ethyl acetate as the eluent to obtain 7b as a white solid (yield 59%, mp
222−223 °C). 1H NMR (400 MHz, CDCl3): δ 1.66 (s, 9H), 2.97 (s,
3H), 3.22 (s, 3H), 7.51 (t, J = 7.6, 1H), 7.67 (t, J = 7.3, 1H), 7.71 (d, J
= 8.0, 1H), 8.01 (s, 1H), 8.08 (d, J = 8.3, 1H), 8.66 (s, 1H). 13C NMR
(100 MHz, CDCl3): δ 28.4, 34.9, 38.9, 81.5, 115.3, 115.6, 121.2, 126.8,
127.0, 128.1, 130.2, 130.6, 130.7, 132.2, 162.4, 168.1. MS (ESI) m/z
calcd for C19H21N3O3Na [M + Na]
+, 362.2; found, 362.1.
Ethyl 5-[Butyl(methyl)carbamoyl]imidazo[1,5-a]quinoline-3-car-
boxylate (7c). This compound was synthesized from 12 according to
the above general procedure and purified by flash chromatography
with ethyl acetate/n-hexane (9:1) as the eluent to obtain 7c as a white
solid (yield 10%, mp 148−149 °C). Because the amide nitrogen of the
compound bears two different substituents, its 1H NMR spectrum
(CDCl3) shows the presence of a (ca. 1:1) mixture of two rotamers in
equilibrium; for the sake of simplification, the integral values have not
been reported. 1H NMR (400 MHz, CDCl3): δ 0.73 (t, J = 7.3), 1.03
(t, J = 7.3), 1.07−1.19 (m), 1.42−1.58 (m), 1.67−1.78 (m), 2.92 (s),
3.18−3.25 (m), 3.61−3.69 (m), 4.47 (q, J = 7.1), 7.50−7.57 (m),
7.66−7.77 (m), 8.02 (s), 8.03 (s), 8.10 (d, J = 8.3), 8.71 (s), 8.72 (s).
MS (ESI) m/z calcd for C20H23N3O3Na [M + Na]
+, 376.2; found,
376.0.
tert-Butyl 5-[Butyl(methyl)carbamoyl]imidazo[1,5-a]quinoline-3-
carboxylate (7d). This compound was prepared from 12 according to
the above general procedure and purified by flash chromatography
with ethyl acetate/n-hexane (9:1) as the eluent to obtain 7d as a
creamy solid (yield 17%, mp 148−150 °C). Because the amide
nitrogen of the compound bears two different substituents, its 1H
NMR spectrum (CDCl3) shows the presence of a (ca. 1:1) mixture of
two rotamers in equilibrium; for the sake of simplification, the integral
values have not been reported. 1H NMR (400 MHz, CDCl3): δ 0.73
(t, J = 7.3), 1.01 (t, J = 7.3), 1.07−1.18 (m), 1.38−1.77 (m), 2.14 (s),
2.92 (s), 3.18 (s), 3.19−3.24 (m), 3.64 (t, J = 7.5), 7.47−7.54 (m),
7.63−7.73 (m), 7.97 (s), 8.08 (d, J = 8.3), 8.68 (s), 8.69 (s). MS (ESI)
m/z calcd for C22H27N3O3Na [M + Na]
+, 404.2; found, 404.2.
Ethyl 5-(Dipropylcarbamoyl)imidazo[1,5-a]quinoline-3-carboxy-
late (7e). The title compound was prepared from 1338 according to
the above general procedure and purified by flash chromatography
with n-hexane−ethyl acetate (1:1) as the eluent to obtain 7e as a white
solid (yield 72%, mp 168−169 °C). 1H NMR (400 MHz, CDCl3): δ
0.71 (t, J = 7.4, 3H), 1.04 (t, J = 7.4, 3H), 1.44 (t, J = 7.1, 3H), 1.48−
1.59 (m, 2H), 1.72−1.87 (m, 2H), 3.15 (br s, 2H), 3.57 (br s, 2H),
4.46 (q, J = 7.1, 2H), 7.50 (t, J = 7.7, 1H), 7.63−7.69 (m, 1H), 7.72 (d,
J = 8.1, 1H), 7.99 (s, 1H), 8.08 (d, J = 8.3, 1H), 8.68 (s, 1H). MS
(ESI) m/z calcd for C21H26N3O3 [M + H]
+, 368.2; found, 367.9.
tert-Butyl 5-(Dipropylcarbamoyl)imidazo[1,5-a]quinoline-3-car-
boxylate (7f). The title compound was prepared from 1338 according
to the above general procedure and purified by flash chromatography
with n-hexane−ethyl acetate (1:1) as the eluent to obtain 7f as a white
solid (yield 48%, mp 159−160 °C). 1H NMR (400 MHz, CDCl3): δ
0.72 (t, J = 7.4, 3H), 1.05 (t, J = 7.4, 3H), 1.37−1.96 (m, 13H), 3.17
(br s, 2H), 3.57 (br s, 2H), 7.52 (t, J = 7.7, 1H), 7.64−7.70 (m, 1H),
7.72 (d, J = 8.0, 1H), 7.96 (s, 1H), 8.08 (d, J = 8.3, 1H), 8.71 (s, 1H).
MS (ESI) m/z calcd for C23H29N3O3Na [M + Na]
+, 418.2; found,
417.9.
Ethyl 5-[Benzyl(methyl)carbamoyl]imidazo[1,5-a]quinoline-3-
carboxylate (7g). The title compound was prepared from 1438
according to the above general procedure and purified by flash
chromatography with ethyl acetate as the eluent to obtain 7g as a
white solid (yield 56%). An analytical sample was obtained by
recrystallization from ethyl acetate−chloroform by slow evaporation
(mp 198−199 °C). Because the amide nitrogen of the compound
bears two different substituents, its 1H NMR spectrum (CDCl3) shows
the presence of a (ca. 6:4) mixture of two rotamers in equilibrium; for
the sake of simplification, the integral values have not been reported.
1H NMR (400 MHz, CDCl3): δ 1.39−1.49 (m), 2.84 (s), 3.14 (s),
4.38−4.51 (m), 4.86 (s), 7.10 (d, J = 7.0), 7.20−7.46 (m), 7.47−7.56
(m), 7.63−7.70 (m), 7.73 (d, J = 8.0), 7.82 (d, J = 8.0), 8.04−8.13
(m), 8.66 (s), 8.67 (s). MS (ESI) m/z calcd for C23H22N3O3 [M +
H]+, 388.2; found, 387.9.
tert-Butyl 5-[Benzyl(methyl)carbamoyl]imidazo[1,5-a]quinoline-
3-carboxylate (7h). The title compound was synthesized from 1438
according to the above general procedure and purified by flash
chromatography with ethyl acetate as the eluent to obtain 7h as a
white solid (yield 36%, mp 92−93 °C). Because the amide nitrogen of
the compound bears two different substituents, its 1H NMR spectrum
(CDCl3) shows the presence of a (ca. 6:4) mixture of two rotamers in
equilibrium; for the sake of simplification, the integral values have not
been reported. 1H NMR (400 MHz, CDCl3): δ 1.65 (s), 1.66 (s), 2.86
(s), 3.14 (s), 4.48 (s), 4.86 (s), 7.11 (d, J = 7.0), 7.19−7.46 (m), 7.49−
7.59 (m), 7.64−7.72 (m), 7.75 (d, J = 8.0), 7.82 (d, J = 8.0), 8.00−8.12
(m), 8.70 (s). MS (ESI) m/z calcd for C25H25N3O3Na [M + Na]
+,
438.2; found, 438.3.
Ethyl 5-(4-Methylpiperazine-1-carbonyl)imidazo[1,5-a]quinoline-
3-carboxylate (7i). The title compound was prepared from 1540
according to the above general procedure and purified by flash
chromatography with ethyl acetate−triethylamine (8:2) as the eluent
to obtain 7i as a white solid (yield 25%, mp 230−231 °C). 1H NMR
(400 MHz, CDCl3): δ 1.44 (t, J = 7.1, 3H), 2.19−2.43 (m, 5H), 2.57
(br s, 2H), 3.24−3.53 (br m, 2H), 3.93 (br s, 2H), 4.46 (q, J = 7.0,
2H), 7.52 (t, J = 7.7, 1H), 7.67 (t, J = 7.8, 1H), 7.75 (d, J = 8.0, 1H),
8.02 (s, 1H), 8.07 (d, J = 8.3, 1H), 8.64 (s, 1H). 13C NMR (100 MHz,
CDCl3): δ 14.5, 41.7, 45.9, 47.1, 54.7, 55.3, 60.7, 115.3, 121.3, 125.9,
126.9, 128.4, 130.4, 130.6, 131.1, 131.9, 163.1, 166.5. MS (ESI) m/z
calcd for C20H23N4O3 [M + H]
+, 367.2; found, 366.9. Anal. Calcd for
C20H22N4O3: C, 65.56; H, 6.05; N, 15.29. Found: C, 65.67; H, 6.44;
N, 15.39.
3-(Ethoxycarbonyl)-4-methylimidazo[1,5-a]quinoline-5-carbox-
ylic Acid (7j). A mixture of 7k (0.37 g, 1.04 mol) in formic acid (15
mL) was stirred at room temperature overnight and then concentrated
under reduced pressure. Purification of the residue by washing with
diethyl ether afforded acid 7j as a white solid (0.29 g, yield 93%, mp
dec >300 °C). 1H NMR (400 MHz, DMSO-d6): δ 1.31 (t, J = 7.0,
3H), 2.59 (s, 3H), 4.30 (q, J = 7.0, 2H), 7.57 (t, J = 7.5, 1H), 7.64 (d, J
= 7.8, 1H), 7.71 (t, J = 7.5, 1H), 8.52 (d, J = 8.3, 1H), 9.28 (s, 1H).
MS (ESI negative ions) m/z calcd for C16H13N2O4 [M − H+]−, 297.1;
found, 297.0.
5-tert-Butyl 3-Ethyl 4-Methylimidazo[1,5-a]quinoline-3,5-dicar-
boxylate (7k). The title compound was prepared from 16 according to
the above general procedure and purified by flash chromatography
with ethyl acetate−n-hexane (8:2) as the eluent to obtain 7k as a white
solid (yield 94%, mp 197−200 °C). 1H NMR (400 MHz, CDCl3): δ
1.47 (t, J = 7.1, 3H), 1.68 (s, 9H), 2.78 (s, 3H), 4.46 (q, J = 7.1, 2H),
7.52 (t, J = 7.6, 1H), 7.61−7.69 (m, 2H), 8.09 (d, J = 8.3, 1H), 8.89 (s,
1H). MS (ESI) m/z calcd for C20H23N2O4 [M + H]
+, 355.2; found,
355.1.
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Ethyl 5-(Dipropylcarbamoyl)-4-methylimidazo[1,5-a]quinoline-
3-carboxylate (7l). The title compound was prepared from 1738
according to the above general procedure and purified by flash
chromatography with ethyl acetate as the eluent to obtain 7l as a off-
white solid (yield 60%, mp 173−174 °C). 1H NMR (400 MHz,
CDCl3): δ 0.65 (t, J = 7.2, 3H), 1.05 (t, J = 7.2, 3H), 1.32−1.56 (m,
5H), 1.74−1.89 (m, 2H), 2.71 (s, 3H), 2.98−3.17 (m, 2H), 3.45−3.72
(m, 2H), 4.43 (q, J = 7.2, 2H), 7.44 (t, J = 7.5, 1H), 7.52−7.62 (m,
2H), 8.03 (d, J = 8.3, 1H), 8.70 (s, 1H). MS (ESI) m/z calcd for
C22H28N3O3 [M + H]
+, 382.2; found, 381.9. Anal. Calcd for
C22H27N3O3: C, 69.27; H, 7.13; N, 11.02. Found: C, 69.13; H, 7.34;
N, 11.19.
tert-Butyl 5-(Dipropylcarbamoyl)-4-methylimidazo[1,5-a]-
quinoline-3-carboxylate (7m). The title compound was prepared
from 1738 according to the above general procedure and purified by
flash chromatography with ethyl acetate as the eluent to obtain 7m as a
white solid (yield 46%, mp 138−139 °C). 1H NMR (400 MHz,
CDCl3): δ 0.66 (t, J = 7.4, 3H), 1.05 (t, J = 7.4, 3H), 1.31−1.55 (m,
2H), 1.66 (s, 9H), 1.75−1.90 (m, 2H), 2.66 (s, 3H), 2.99−3.18 (m,
2H), 3.45−3.56 (m, 1H), 3.62−3.74 (m, 1H), 7.45 (t, J = 7.6, 1H),
7.53−7.63 (m, 2H), 8.01 (d, J = 8.3, 1H), 8.65 (s, 1H). MS (ESI) m/z
calcd for C24H31N3O3Na [M + Na]
+, 432.2; found, 432.1. Anal. Calcd
for C24H31N3O3: C, 70.39; H, 7.63; N, 10.26. Found: C, 70.22; H,
7.44; N, 10.23.
Ethyl 4-Methyl-5-[methyl(prop-2-ynyl)carbamoyl]imidazo[1,5-a]-
quinoline-3-carboxylate (7n). A mixture of acid 7j (0.80 g, 2.68
mmol) in 6.0 mL of thionyl chloride was heated to reflux for 3 h and
then concentrated under reduced pressure. The residue was dissolved
into 6.0 mL of dichloromethane, and the resulting solution was treated
with N-methylpropargylamine (0.43 mL, 5.1 mmol). The reaction
mixture was stirred at room temperature for 30 min and then
partitioned between dichloromethane and water. The organic layer
was washed with water, dried over sodium sulfate, and concentrated
under reduced pressure. The resulting residue was purified by flash
chromatography with n-hexane−ethyl acetate (1:1) as the eluent to
obtain 7n as a white solid (0.82 g, yield 88%, mp 219−220 °C). The
1H NMR spectrum (CDCl3) of the compound shows the presence of
the minor rotamer only in low amount. For the sake of simplification,
only the signals of the major rotamer have been reported. 1H NMR
(400 MHz, CDCl3): δ 1.46 (t, J = 7.1, 3H), 2.34 (br s, 1H), 2.72 (s,
3H), 2.94 (s, 3H), 4.38−4.51 (m, 3H), 4.59 (d, J = 17.2, 1H), 7.45−
7.51 (m, 1H), 7.55 (d, J = 8.0, 1H), 7.62 (t, J = 7.7, 1H), 8.04 (d, J =
8.3, 1H), 8.68 (s, 1H). MS (ESI) m/z calcd for C20H20N3O3 [M +
H]+, 350.2; found, 349.9.
Ethyl 5-[Benzyl(methyl)carbamoyl]-4-methylimidazo[1,5-a]-
quinoline-3-carboxylate (7o). The title compound was prepared
from 1838 according to the above general procedure and purified by
flash chromatography with ethyl acetate−n-hexane (8:2) as the eluent
to obtain 7o as a white solid (yield 26%, mp 214−215 °C). The 1H
NMR spectrum (CDCl3) of the compound shows the presence of the
minor rotamer only in trace amounts. For the sake of simplification,
only the signals of the major rotamer have been reported. 1H NMR
(400 MHz, CDCl3): δ 1.44 (t, J = 7.1, 3H), 2.70 (s, 3H), 2.75 (s, 3H),
4.42 (q, J = 7.1, 2H), 4.79 (d, J = 14.1, 1H), 4.99 (d, J = 14.1, 1H),
7.30−7.61 (m, 8H), 8.02 (d, J = 8.3, 1H), 8.69 (s, 1H). MS (ESI) m/z
calcd for C24H24N3O3 [M + H]
+, 402.2; found, 401.9.
tert-Butyl 5-[Benzyl(methyl)carbamoyl]-4-methylimidazo[1,5-a]-
quinoline-3-carboxylate (7p). The title compound was prepared from
1838 according to the above general procedure and purified by flash
chromatography with ethyl acetate−n-hexane (8:2) as the eluent to
obtain 7p as a white solid (yield 46%, mp 123−126 °C). The 1H NMR
spectrum (CDCl3) of the compound shows the presence of the minor
rotamer only in trace amounts. For the sake of simplification, only the
signals of the major rotamer have been reported. 1H NMR (400 MHz,
CDCl3): δ 1.64 (s, 9H), 2.64 (s, 3H), 2.74 (s, 3H), 4.74 (d, J = 14.1,
1H), 5.01 (d, J = 14.1, 1H), 7.29−7.58 (m, 8H), 7.99 (d, J = 8.3, 1H),
8.65 (s, 1H). MS (ESI) m/z calcd for C26H28N3O3 [M + H]
+, 430.2;
found, 429.9.
Ethyl 5-(Dipropylcarbamoyl)-4-ethylimidazo[1,5-a]quinoline-3-
carboxylate (7q). The title compound was prepared from 1938
according to the above general procedure and purified by flash
chromatography with ethyl acetate−n-hexane (7:3) as the eluent to
obtain 7q as a white solid (yield 27%, mp 114−115 °C). 1H NMR
(400 MHz, CDCl3): δ 0.65 (t, J = 7.4, 3H), 1.06 (t, J = 7.4, 3H), 1.21
(t, J = 7.4, 3H), 1.33−1.57 (m, 5H), 1.74−1.90 (m, 2H), 2.74−2.88
(m, 1H), 2.96−3.16 (m, 2H), 3.46−3.59 (m, 1H), 3.61−3.78 (m, 2H),
4.38−4.55 (m, 2H), 7.48 (t, J = 7.6, 1H), 7.55−7.65 (m, 2H), 8.06 (d,
J = 8.3, 1H), 8.79 (s, 1H). MS (ESI) m/z calcd for C23H29N3O3Na [M
+ Na]+, 418.2; found, 418.3. Anal. Calcd for C23H29N3O3·0.25H2O: C,
69.06; H, 7.43; N, 10.51. Found: C, 69.14; H, 7.50; N, 10.25.
tert-Butyl 5-(Dipropylcarbamoyl)-4-ethylimidazo[1,5-a]-
quinoline-3-carboxylate (7r). The title compound was prepared
from 1938 according to the above general procedure and purified by
flash chromatography with ethyl acetate−n-hexane (8:2) as the eluent
to obtain 7r as white crystals (yield 15%, mp 160−161 °C). 1H NMR
(400 MHz, CDCl3): δ 0.65 (t, J = 7.4, 3H), 1.05 (t, J = 7.4, 3H), 1.18
(t, J = 7.4, 3H), 1.30−1.56 (m, 2H), 1.67 (s, 9H), 1.76−1.89 (m, 2H),
2.71−2.77 (m, 1H), 2.97−3.15 (m, 2H), 3.46−3.57 (m, 1H), 3.61−
3.72 (m, 2H), 7.45 (t, J = 7.6, 1H), 7.52−7.61 (m, 2H), 8.02 (d, J =
8.3, 1H), 8.67 (s, 1H). MS (ESI) m/z calcd for C25H33N3O3Na [M +
Na]+, 446.2; found, 446.1. Anal. Calcd for C25H33N3O3: C, 70.89; H,
7.85; N, 9.92. Found: C, 71.18; H, 8.15; N, 9.82.
Ethyl 5-(Diethylcarbamoyl)-4-propylimidazo[1,5-a]quinoline-3-
carboxylate (7s). The title compound was prepared from 2038
according to the above general procedure and purified by flash
chromatography with ethyl acetate−n-hexane (8:2) as the eluent to
obtain 7s as a white solid (yield 21%). An analytical sample was
obtained by recrystallization from diethyl ether by slow evaporation
(X-ray quality pale-yellow crystals, mp 103−104 °C). 1H NMR (400
MHz, CDCl3): δ 0.92−1.07 (m, 6H), 1.36 (t, J = 7.1, 3H), 1.43 (t, J =
7.1, 3H), 1.50−1.67 (m, 2H), 2.61−2.79 (m, 1H), 3.07−3.30 (m, 2H),
3.50−3.69 (m, 2H), 3.75−3.89 (m, 1H), 4.35−4.53 (m, 2H), 7.43 (t, J
= 7.5, 1H), 7.52−7.60 (m, 2H), 8.01 (d, J = 8.2, 1H), 8.67 (s, 1H). 13C
NMR (100 MHz, CDCl3): δ 12.7, 14.0, 14.1, 14.5, 23.6, 33.1, 38.9,
43.0, 61.1, 114.9, 121.6, 126.3, 126.6, 127.2, 128.0, 128.5, 129.2, 129.5,
130.4, 130.7, 163.4, 167.3. MS (ESI) m/z calcd for C22H28N3O3 [M +
H]+, 382.2; found, 381.9. Anal. Calcd for C22H27N3O3: C, 69.27; H,
7.13; N, 11.02. Found: C, 69.45; H, 7.40; N, 11.05.
tert-Butyl 5-(Diethylcarbamoyl)-4-propylimidazo[1,5-a]-
quinoline-3-carboxylate (7t). The title compound was prepared
from 2038 according to the above general procedure and purified by
flash chromatography with ethyl acetate−n-hexane (8:2) as the eluent
to obtain 7t as a white solid (yield 55%). An analytical sample was
obtained by recrystallization from diethyl ether by slow evaporation
(X-ray quality pale-yellow prisms, mp 142−143 °C). 1H NMR (400
MHz, CDCl3): δ 0.89−1.05 (m, 6H), 1.35 (t, J = 7.0, 3H), 1.48−1.58
(m, 2H), 1.64 (s, 9H), 2.55−2.74 (m, 1H), 3.07−3.31 (m, 2H), 3.50−
3.65 (m, 2H), 3.72−3.85 (m, 1H), 7.41 (t, J = 7.5, 1H), 7.51−7.61 (m,
2H), 7.99 (d, J = 8.2, 1H), 8.63 (s, 1H). 13C NMR (100 MHz,
CDCl3): δ 12.7, 14.0, 23.2, 28.3, 32.9, 38.9, 43.0, 81.5, 114.8, 121.6,
126.3, 126.4, 127.7, 128.5, 129.0, 129.1, 129.2, 129.5, 130.0, 163.3,
167.4. MS (ESI) m/z calcd for C24H31N3O3Na [M + Na]
+, 432.2;
found, 431.9. Anal. Calcd for C24H31N3O3: C, 70.39; H, 7.63; N, 10.26.
Found: C, 70.62; H, 7.90; N, 10.00.
Ethyl 5-(Dipropylcarbamoyl)-4-propylimidazo[1,5-a]quinoline-3-
carboxylate (7u). The title compound was prepared from 2138
according to the above general procedure and purified by flash
chromatography with ethyl acetate−n-hexane (8:2) as the eluent to
obtain 7u as a white solid (yield 5%, mp 143−144 °C). 1H NMR (400
MHz, CDCl3): δ 0.63 (t, J = 7.1, 3H), 0.98 (t, J = 7.0, 3H), 1.04 (t, J =
7.1, 3H), 1.31−1.51 (m, 5H), 1.53−1.64 (m, 2H), 1.74−1.89 (m, 2H),
2.58−2.72 (m, 1H), 2.98−3.16 (m, 2H), 3.37−3.51 (m, 1H), 3.60−
3.81 (m, 2H), 4.38−4.52 (m, 2H), 7.43 (t, J = 7.4, 1H), 7.51−7.63 (m,
2H), 8.01 (d, J = 7.9, 1H), 8.69 (s, 1H). 13C NMR (100 MHz,
CDCl3): δ 11.3, 11.7, 14.1, 14.5, 20.6, 21.7, 23.6, 33.2, 46.4, 50.6, 61.1,
114.8, 121.6, 126.5, 127.2, 128.0, 128.5, 129.2, 129.5, 130.4, 130.7,
163.4, 167.7. MS (ESI) m/z calcd for C24H32N3O3 [M + H]
+, 410.2;
found, 409.9. Anal. Calcd for C24H31N3O3: C, 70.39; H, 7.63; N, 10.26.
Found: C, 70.01; H, 7.83; N, 10.21.
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tert-Butyl 5-(Dipropylcarbamoyl)-4-propylimidazo[1,5-a]-
quinoline-3-carboxylate (7v). The title compound was prepared
from 2138 according to the above general procedure and purified by
flash chromatography with ethyl acetate−n-hexane (8:2) as the eluent
to obtain 7v as a white solid (yield 4%, mp 163−164 °C). 1H NMR
(400 MHz, CDCl3): δ 0.64 (t, J = 6.5, 3H), 0.96 (t, J = 6.3, 3H), 1.04
(t, J = 6.5, 3H), 1.32−1.93 (m, 15H), 2.46−2.69 (m, 1H), 2.94−3.22
(m, 2H), 3.33−3.51 (m, 1H), 3.58−3.85 (m, 2H), 7.42 (t, J = 6.9,
1H), 7.51−7.62 (m, 2H), 8.00 (d, J = 7.9, 1H), 8.64 (s, 1H). 13C NMR
(100 MHz, CDCl3): δ 11.3, 11.7, 14.0, 20.6, 21.8, 23.2, 28.3, 33.0,
46.4, 50.6, 81.5, 114.8, 121.6, 126.4, 126.5, 127.6, 128.5, 129.0, 129.1,
129.2, 129.5, 130.0, 163.3, 167.8. MS (ESI) m/z calcd for C26H36N3O3
[M + H]+, 438.3; found, 437.9. Anal. Calcd for C26H35N3O3: C, 71.37;
H, 8.06; N, 9.60. Found: C, 71.70; H, 8.25; N, 9.46.
Ethyl 5-(Dipropylcarbamoyl)-7-fluoroimidazo[1,5-a]quinoline-3-
carboxylate (7w). The title compound was prepared from 22
according to the above general procedure and purified by flash
chromatography with n-hexane−ethyl acetate (1:1) as the eluent to
obtain 7w as a off-white solid (yield 21%, mp 175−177 °C). 1H NMR
(400 MHz, CDCl3): δ 0.71 (t, J = 7.3, 3H), 1.03 (t, J = 7.3, 3H), 1.43
(t, J = 7.1, 3H), 1.47−1.59 (m, 2H), 1.72−1.85 (m, 2H), 3.09−3.22
(m, 2H), 3.55 (br s, 2H), 4.45 (q, J = 7.1, 2H), 7.33−7.42 (m, 2H),
8.02 (s, 1H), 8.05−8.13 (m, 1H), 8.62 (s, 1H). MS (ESI) m/z calcd
for C21H24FN3O3Na [M + Na]
+, 408.2; found, 408.5.
Ethyl 5-[Benzyl(methyl)carbamoyl]-7-fluoroimidazo[1,5-a]-
quinoline-3-carboxylate (7x). The title compound was prepared
from 23 according to the above general procedure and purified by flash
chromatography with ethyl acetate−n-hexane (8:2) as the eluent to
obtain 7x as a white solid (yield 15%). An analytical sample was
obtained by recrystallization from ethyl acetate−dichloromethane by
slow evaporation (mp 180−182 °C). Because the amide nitrogen of
the compound bears two different substituents, its 1H NMR spectrum
(CDCl3) shows the presence of a (ca. 6:4) mixture of two rotamers in
equilibrium; for the sake of simplification, the integral values have not
been reported. 1H NMR (400 MHz, CDCl3): δ 1.39−1.52 (m), 2.87
(s), 3.16 (s), 4.36−4.49 (m), 4.50 (s), 4.86 (s), 7.11 (d, J = 7.1), 7.21−
7.55 (m), 8.04−8.10 (m), 8.11 (s), 8.14 (s), 8.62 (s), 8.63 (s). MS
(ESI) m/z calcd for C23H21FN3O3 [M + H]
+, 406.2; found, 406.3.
Ethyl 5-[Benzyl(methyl)carbamoyl]-7-bromoimidazo[1,5-a]-
quinoline-3-carboxylate (7y). The title compound was prepared
from 24 according to the above general procedure (except that the
reaction was carried out at 0−5 °C for 2 h and then at room
temperature for 2 h) and purified by flash chromatography with ethyl
acetate−petroleum ether (7:3) as the eluent to obtain 7y as a white
solid (yield 62%, mp 177−178 °C). Because the amide nitrogen of the
compound bears two different substituents, its 1H NMR spectrum
(CDCl3) shows the presence of a (ca. 6:4) mixture of two rotamers in
equilibrium; for the sake of simplification, the integral values have not
been reported. 1H NMR (400 MHz, CDCl3): δ 1.32−1.49 (m), 2.86
(s), 3.18 (s), 4.34−4.57 (m), 4.87 (s), 7.09−7.12 (m), 7.22−7.54 (m),
7.78 (d, J = 8.2), 7.86−8.16 (m), 8.63 (s). MS (ESI) m/z calcd for
C23H21BrN3O3 [M + H]
+, 466.1; found, 466.3.
Ethyl 5-[Benzyl(methyl)carbamoyl]-7-[(trimethylsilyl)ethynyl]-
imidazo[1,5-a]quinoline-3-carboxylate (7aa). To a solution of 7y
(25 mg, 0.0536 mmol) in dry TEA (5.0 mL), ethynyltrimethylsilane
(0.045 mL, 0.32 mmol) and Pd(PPh3)2(OAc)2 (4.0 mg, 0.0053 mmol)
were added. The reaction mixture was allowed to stir at room
temperature for 30 min, then refluxed for 20 h, and finally filtered and
concentrated under reduced pressure. The residue was dissolved into
dichloromethane, and the organic layer was washed with a saturated
solution of sodium bicarbonate, dried over sodium sulfate, and
concentrated under reduced pressure. Purification of the residue by
flash chromatography with ethyl acetate−n-hexane (7:3) as the eluent
gave 7aa as an oil which slowly crystallized on standing (12 mg, yield
46%). Because the amide nitrogen of this compound bears two
different substituents, its 1H NMR spectrum shows the presence of a
(ca. 6:4) mixture of two different rotamers in equilibrium; for the sake
of simplification, the integral values have not been given. 1H NMR
(400 MHz, CDCl3): δ 0.29 (s), 1.38−1.48 (m), 2.86 (s), 3.19 (s),
4.36−4.55 (m), 4.88 (s), 7.13 (d, J = 7.5), 7.18−7.50 (m), 7.75 (d, J =
8.7), 7.83 (s), 7.90 (s), 7.95−8.12 (m), 8.61 (s), 8.62 (s). MS (ESI)
m/z calcd for C28H30N3O3Si [M + H]
+, 484.2; found, 484.4.
Ethyl 5-[Benzyl(methyl)carbamoyl]-7-ethynylimidazo[1,5-a]-
quinoline-3-carboxylate (7z). To a solution of 7aa (50 mg, 0.103
mmol) in THF (15 mL), a solution (1 M in THF) of Bu4NF (0.12
mL, 0.12 mmol) was added. The reaction mixture was stirred at room
temperature for 1 h, then diluted with water and extracted with ethyl
acetate. The organic layer was washed with brine, dried over sodium
sulfate, and concentrated under reduced pressure. Purification of the
residue by flash chromatography with ethyl acetate as the eluent gave
7z as a yellow glassy solid (21 mg, yield 49%). Because the amide
nitrogen of this compound bears two different substituents, its 1H
NMR spectrum shows the presence of a (ca. 6:4) mixture of two
different rotamers in equilibrium; for the sake of simplification, the
integral values have not been given. 1H NMR (400 MHz, CDCl3): δ
1.39−1.49 (m), 2.86 (s), 3.18 (s), 3.19 (s), 3.22 (s), 4.40−4.51 (m),
4.87 (s), 7.12 (d, J = 7.2), 7.22−7.49 (m), 7.77 (d, J = 8.2), 7.88 (s),
7.95 (s), 7.98−8.12 (m), 8.63 (s), 8.64 (s). MS (ESI) m/z calcd for
C25H21N3O3Na [M + Na]
+, 434.2; found, 434.5.
Ethyl 5-Phenylimidazo[1,5-a]quinoline-3-carboxylate (8a). This
compound was prepared from 2861 (0.20 g, 0.834 mmol), ethyl
isocyanoacetate (0.28 mL, 2.56 mmol), and potassium tert-butoxide
(0.27 g, 2.41 mmol) according to the general procedure described for
the synthesis of 7a−i,k−m,o−y and purified by flash chromatography
with ethyl acetate as the eluent to obtain 8a as a white solid (0.24 g,
yield 91%, mp 244−245 °C). 1H NMR (400 MHz, CDCl3): δ 1.43 (t,
J = 7.0, 3H), 4.45 (q, J = 7.0, 2H), 7.36−7.54 (m, 6H), 7.65 (t, J = 7.6,
1H), 7.77 (d, J = 8.1, 1H), 8.02 (s, 1H), 8.09 (d, J = 8.2, 1H), 8.64 (s,
1H). 13C NMR (100 MHz, CDCl3): δ 14.6, 60.5, 115.1, 117.2, 123.9,
124.6, 126.1, 127.8, 128.1, 128.3, 128.6, 129.6, 130.7, 132.4, 138.1,
138.4, 163.4. MS (ESI) m/z calcd for C20H16N2O2Na [M + Na]
+,
339.1; found, 338.8.
tert-Butyl 5-Phenylimidazo[1,5-a]quinoline-3-carboxylate (8b).
This compound was prepared from 2861 (1.0 g, 4.17 mmol), tert-
butyl isocyanoacetate (1.8 mL, 12.4 mmol), and potassium tert-
butoxide (1.4 g, 12.5 mmol) according to the general procedure
described for the synthesis of 7a−i,k−m,o−y and purified by flash
chromatography with n-hexane−ethyl acetate (1:1) as the eluent to
obtain 8b as a white solid (1.0 g, yield 70%, mp 231−233 °C). 1H
NMR (400 MHz, CDCl3): δ 1.66 (s, 9H), 7.37−7.55 (m, 6H), 7.67 (t,
J = 7.5, 1H), 7.79 (d, J = 8.0, 1H), 8.04 (s, 1H), 8.11 (d, J = 8.1, 1H),
8.68 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 28.5, 81.1, 115.1, 117.5,
123.8, 125.9, 126.0, 127.5, 128.1, 128.2, 128.6, 129.5, 130.8, 132.0,
138.0, 138.2, 162.9. MS (ESI) m/z calcd for C22H20N2O2Na [M +
Na]+, 367.1; found, 367.2.
N,N-Dimethyl-5-phenylimidazo[1,5-a]quinoline-3-carboxamide
(8c). A mixture of acid 32 (0.40 g, 1.39 mmol) in acetonitrile (17 mL)
and water (34 mL) was treated with a 0.1 M solution of sodium
carbonate up to pH 7.5 and then with a solution of 2,3,5,6-
terafluorophenol (0.46 g, 2.77 mmol) in acetonitrile (1.0 mL) and
EDC hydrochloride (0.53 g, 2.76 mmol). The reaction mixture was
stirred at room temperature for 4 h, and the precipitate was collected
by filtration and purified by flash chromatography to obtain the
corresponding 2,3,5,6-terafluorophenyl ester as an off-white solid (0.34
g, yield 56%, mp 243−245 °C), which was promptly used in the
subsequent step without any further purification. 1H NMR (200 MHz,
CDCl3): δ 6.91−7.08 (m, 1H), 7.40−7.52 (m, 6H), 7.67−7.82 (m,
2H), 7.98 (s, 1H), 8.15 (d, J = 8.3, 1H), 8.80 (s, 1H). MS (ESI): m/z
459 (M + Na+). To a solution of the 2,3,5,6-tetrafluorophenyl ester
(0.10 g, 0.229 mmol) in dry THF (15 mL), a 2 M solution of
dimethylamine in THF (0.35 mL, 0.70 mmol) was added. The
reaction mixture was stirred at room temperature for 1 h and then
concentrated under reduced pressure. Purification of the residue by
flash chromatography with ethyl acetate−n-hexane (7:3) as the eluent
gave 8c as a white solid (52 mg, yield 72%, mp 235−236 °C). 1H
NMR (400 MHz, CDCl3): δ 3.15 (br s, 3H), 3.57 (br s, 3H), 7.41−
7.49 (m, 6H), 7.63 (t, J = 7.7, 1H), 7.77 (d, J = 8.2, 1H), 8.04−8.11
(m, 2H), 8.60 (s, 1H). MS (ESI) m/z calcd for C20H18N3O [M + H]
+,
316.1; found, 316.1.
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N-Benzyl-N-methyl-5-phenylimidazo[1,5-a]quinoline-3-carboxa-
mide (8d). This compound was prepared by using the same procedure
described for 8c (except that N-methylbenzylamine was used instead
of dimethylamine) and purified by flash chromatography with n-
hexane−ethyl acetate (1:1) as the eluent to obtain 8d as a white solid
(yield 48%, mp 157−159 °C). Because the amide nitrogen of this
compound bears two different substituents, its 1H NMR spectrum
shows the presence of a (ca. 54:46) mixture of two different rotamers
in equilibrium; for the sake of simplification, the integral values have
not been given. 1H NMR (400 MHz, CDCl3): δ 3.03 (br s), 3.51 (br
s), 4.81 (br s), 5.46 (br s), 7.28−7.54 (m), 7.63 (t, J = 7.3), 7.79 (d, J =
8.1), 8.06 (br s), 8.18 (br s), 8.58 (br s). MS (ESI) m/z calcd for
C26H22N3O [M + H]
+, 392.2; found, 392.0.
tert-Butyl 4-Methyl-5-phenylimidazo[1,5-a]quinoline-3-carboxy-
late (8e). This compound was prepared from 2942 (1.0 g, 3.94 mmol),
tert-butyl isocyanoacetate (1.7 mL, 11.7 mmol), and potassium tert-
butoxide (1.3 g, 11.6 mmol) according to the general procedure
described for the synthesis of 7a−i,k−m,o−y and purified by flash
chromatography with n-hexane−ethyl acetate (1:1) as the eluent to
obtain 8e as a creamy solid (0.30 g, yield 21%, mp 204−205 °C). 1H
NMR (400 MHz, CDCl3): δ 1.65 (s, 9H), 2.43 (s, 3H), 7.18 (d, J =
8.1, 1H), 7.22−7.26 (m, 2H), 7.27−7.35 (m, 1H), 7.46−7.56 (m, 4H),
8.03 (d, J = 8.3, 1H), 8.69 (s, 1H). MS (ESI) m/z calcd for
C23H22N2O2Na [M + Na]
+, 381.2; found, 381.2.
N-Benzyl-N,4-dimethyl-5-phenylimidazo[1,5-a]quinoline-3-car-
boxamide (8f). This compound was prepared from acid 33 by using
the same procedure described for 8c (except that N-methylbenzyl-
amine was used instead of dimethylamine) and purified by flash
chromatography with ethyl acetate as the eluent to obtain 8f as a pale-
yellow glassy solid (yield 67%). Because the amide nitrogen of this
compound bears two different substituents, its 1H NMR spectrum
shows the presence of a (ca. 54:46) mixture of two different rotamers
in equilibrium; for the sake of simplification, the integral values have
not been given. 1H NMR (400 MHz, CDCl3): δ 2.24 (s), 3.01 (s),
3.08 (s), 4.72 (s), 4.82 (s), 7.16−7.36 (m), 7.39 (d, J = 7.3), 7.42−7.57
(m), 7.89−8.08 (m), 8.70 (s), 8.74 (s). MS (ESI) m/z calcd for
C27H24N3O [M + H]
+, 406.2; found, 406.3.
Diethyl 5-Phenylimidazo[1,5-a]quinoline-3,4-dicarboxylate (8g).
This compound was prepared from 3062 (0.36 g, 1.15 mmol), ethyl
isocyanoacetate (0.38 mL, 3.48 mmol), and potassium tert-butoxide
(0.37 g, 3.30 mmol) according to the general procedure described for
the synthesis of 7a−i,k−m,o−y and purified by flash chromatography
with ethyl acetate as the eluent to obtain 8g as a white solid (0.26 g,
yield 58%, mp 163−164 °C). 1H NMR (400 MHz, CDCl3): δ 0.97 (t,
J = 7.1, 3H), 1.40 (t, J = 7.1, 3H), 4.12 (q, J = 7.1, 2H), 4.39 (q, J = 7.1,
2H), 7.29−7.40 (m, 4H), 7.42−7.50 (m, 3H), 7.62−7.68 (m, 1H),
8.08 (d, J = 8.4, 1H), 8.72 (s, 1H). 13C NMR (100 MHz, CDCl3): δ
13.6, 14.5, 60.7, 61.4, 114.7, 123.3, 124.2, 125.6, 126.4, 127.7, 128.2,
128.5, 129.1, 130.0, 130.2, 130.4, 135.0, 136.3, 162.7, 165.3. MS (ESI)
m/z calcd for C23H20N2O4Na [M + Na]
+, 411.1; found, 410.8.
Ethyl 4-(2-Ethoxy-2-oxoethyl)-5-phenylimidazo[1,5-a]quinoline-
3-carboxylate (8h). This compound was prepared from 3142 (0.20
g, 0.614 mmol), ethyl isocyanoacetate (0.24 mL, 2.20 mmol), and
potassium tert-butoxide (0.20 g, 1.78 mmol) according to the general
procedure described for the synthesis of 7a−i,k−m,o−y and purified
by flash chromatography with ethyl acetate as the eluent to obtain 8h
as a white solid (0.14 g, yield 57%, mp 186−187 °C). 1H NMR (400
MHz, CDCl3): δ 1.18 (t, J = 7.1, 3H), 1.43 (t, J = 7.1, 3H), 4.10 (q, J =
7.1, 2H), 4.15 (s, 2H), 4.40 (q, J = 7.1, 2H), 7.19 (d, J = 8.2, 1H),
7.22−7.27 (m, 2H), 7.34 (t, J = 7.7, 1H), 7.44−7.51 (m, 3H), 7.61 (t, J
= 7.8, 1H), 8.08 (d, J = 8.3, 1H), 8.73 (s, 1H). MS (ESI) m/z calcd for
C24H22N2O4Na [M + Na]
+, 425.2; found, 424.8.
Ethyl 4-Hydroxymethyl-5-phenylimidazo[1,5-a]quinoline-3-car-
boxylate (8i). To a solution of 36 (1.0 g, 2.17 mmol) in THF (40
mL) cooled at 0−5 °C, a solution (1 M in THF) of Bu4NF (4.3 mL,
4.3 mmol) was added. The reaction mixture was stirred at the same
temperature for 30 min and overnight at room temperature, then
diluted with water, and extracted with diethyl ether. The organic layer
was washed with brine, dried over sodium sulfate, and concentrated
under reduced pressure. Purification of the residue by flash
chromatography with ethyl acetate as the eluent gave 8i as a white
solid (0.20 g, yield 27%, mp 192−193 °C). 1H NMR (400 MHz,
CDCl3): δ 1.49 (t, J = 7.1, 3H), 4.51 (q, J = 7.1, 2H), 4.64 (s, 2H),
5.13 (br s, 1H), 7.32 (d, J = 8.1, 1H), 7.35−7.41 (m, 3H), 7.45−7.56
(m, 3H), 7.64 (t, J = 7.7, 1H), 8.09 (d, J = 8.3, 1H), 8.78 (s, 1H). MS
(ESI) m/z calcd for C21H18N2O3Na [M + Na]
+, 369.1; found, 368.8.
Ethyl 10,11-Dihydro-9H-cyclopenta[c]imidazo[1,5-a]quinoline-1-
carboxylate (9). This compound was prepared from 3743 (0.16 g,
0.786 mmol), ethyl isocyanoacetate (0.26 mL, 2.38 mmol), and
potassium tert-butoxide (0.25 g, 2.23 mmol) according to the general
procedure described for the synthesis of 7a−i,k−m,o−y and purified
by flash chromatography with ethyl acetate as the eluent to obtain 9 as
an off-white solid (0.15 g, yield 68%, mp 200−201 °C). 1H NMR (400
MHz, CDCl3): δ 1.46 (t, J = 7.1, 3H), 2.20−2.33 (m, 2H), 3.14 (t, J =
7.6, 2H), 3.59 (t, J = 7.4, 2H), 4.44 (q, J = 7.1, 2H), 7.50 (t, J = 7.5,
1H), 7.59 (t, J = 7.7, 1H), 7.70 (d, J = 7.8, 1H), 8.02 (d, J = 8.3, 1H),
8.61 (s, 1H). MS (ESI) m/z calcd for C17H17N2O2 [M + H]
+, 281.1;
found, 280.9.
General Procedure for the Synthesis of Target Imidazo[1,5-
a]quinoxaline Derivatives 10a−d. A solution of the suitable 4-acetyl-
3,4-dihydroquinoxalin-2(1H)-one derivative (38 or 39) in dry THF
was cooled at 0 °C for 10 min under argon and then treated with
potassium tert-butoxide. The resulting mixture was allowed to warm at
room temperature and stirred for 45 min under argon atmosphere.
Then, it was cooled to −55 °C, diethyl chlorophosphate was added,
and the resulting mixture was stirred at −55 °C for 15 min and finally
at room temperature for 45 min. The reaction mixture was cooled
again at −55 °C and then treated with the suitable isocyanoacetate and
potassium tert-butoxide. The resulting mixture was allowed to stir at
−55 °C for 2 h and finally at room temperature for 30 min. Then,
glacial acetic acid was added and the reaction mixture was
concentrated under reduced pressure. The residue was dissolved
into CHCl3 and washed with water and with brine. The organic layer
was dried over sodium sulfate and concentrated under reduced
pressure. Purification of the residue by flash chromatography with the
appropriate eluent gave the expected target derivative (10a−d).
Ethyl 5-Acetyl-4,5-dihydroimidazo[1,5-a]quinoxaline-3-carboxy-
late (10a). This compound was prepared from 3831 (2.0 g, 10.5
mmol), potassium tert-butoxide (1.3 g, 11.6 mmol), diethyl
chlorophosphate (1.68 mL, 11.6 mmol), ethyl isocyanoacetate (1.8
mL, 16.5 mmol), and potassium tert-butoxide (1.3 g, 11.6 mmol)
according to the above general procedure and purified by flash
chromatography with ethyl acetate as the eluent to obtain 10a as an
off-white crystalline solid (1.22 g, yield 41%). An analytical sample was
obtained by recrystallization from ethyl acetate (colorless prisms, mp
173−174 °C). 1H NMR (400 MHz, CDCl3): δ 1.39 (t, J = 7.1, 3H),
2.25 (s, 3H), 4.37 (q, J = 7.1, 2H), 5.24 (s, 2H), 7.30−7.59 (m, 4H),
8.02 (s, 1H). MS (ESI) m/z calcd for C15H15N3O3Na [M + Na]
+,
308.1; found, 307.9.
tert-Butyl 5-Acetyl-4,5-dihydroimidazo[1,5-a]quinoxaline-3-car-
boxylate (10b). This compound was prepared from 3831 (1.0 g,
5.25 mmol), potassium tert-butoxide (0.65 g, 5.79 mmol), diethyl
chlorophosphate (0.84 mL, 5.81 mmol), tert-butyl isocyanoacetate
(0.92 mL, 6.32 mmol), and potassium tert-butoxide (0.65 g, 5.78
mmol) according to the above general procedure and purified by flash
chromatography with ethyl acetate as the eluent to obtain 10b as a
white solid (0.69 g, yield 42%). An analytical sample was obtained by
recrystallization from ethyl acetate (colorless crystals, mp 184−185 °C,
lit.23 150−152 °C). 1H NMR (400 MHz, CDCl3): δ 1.63 (s, 9H), 2.28
(br s, 3H), 5.26 (br s, 2H), 7.29−7.59 (m, 4H), 8.01 (s, 1H). MS
(ESI) m/z calcd for C17H19N3O3Na [M + Na]
+, 336.1; found, 335.8.
Ethyl 5-Acetyl-7-fluoro-4,5-dihydroimidazo[1,5-a]quinoxaline-3-
carboxylate (10c). This compound was prepared from 39 (150 mg,
0.72 mmol), potassium tert-butoxide (87 mg, 0.78 mmol), diethyl
chlorophosphate (0.11 mL, 0.76 mmol), ethyl isocyanoacetate (0.12
mL, 1.1 mmol), and potassium tert-butoxide (87 mg, 0.78 mmol)
according to the above general procedure and purified by flash
chromatography with ethyl acetate as the eluent to obtain 10c as a
light-brown solid (70 mg, yield 32%). An analytical sample was
obtained by recrystallization from cyclohexane−ethyl acetate (colorless
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crystals, mp 149−150 °C). 1H NMR (400 MHz, CDCl3): δ 1.42 (t, J =
7.1, 3H), 2.33 (s, 3H), 4.41 (q, J = 7.1, 2H), 5.25 (s, 2H), 7.02−7.12
(m, 1H), 7.41 (br s, 1H), 7.49−7.59 (m, 1H), 7.99 (s, 1H). MS (ESI)
m/z calcd for C15H14FN3O3Na [M + Na]
+, 326.1; found, 325.8.
tert-Butyl 5-Acetyl-7-fluoro-4,5-dihydroimidazo[1,5-a]-
quinoxaline-3-carboxylate (10d). This compound was prepared
from 39 (60 mg, 0.29 mmol), potassium tert-butoxide (37 mg, 0.33
mmol), diethyl chlorophosphate (0.048 mL, 0.33 mmol), tert-butyl
isocyanoacetate (0.067 mL, 0.46 mmol), and potassium tert-butoxide
(37 mg, 0.33 mmol) according to the above general procedure and
purified by flash chromatography with ethyl acetate as the eluent to
obtain 10d as a light-brown solid (30 mg, yield 31%). An analytical
sample was obtained by recrystallization from ethyl acetate (colorless
crystals, mp 208−209 °C). 1H NMR (400 MHz, CDCl3): δ 1.62 (s,
9H), 2.34 (s, 3H), 5.23 (s, 2H), 7.03−7.11 (m, 1H), 7.39 (br s, 1H),
7.46−7.55 (m, 1H), 7.96 (s, 1H). MS (ESI) m/z calcd for
C17H18FN3O3Na [M + Na]
+, 354.1; found, 353.8.
2-Chloro-N,N-dimethylquinoline-4-carboxamide (11). This com-
pound was prepared from of 2-hydroxy-4-quinolinecarboxylic acid and
dimethylamine by following the procedure described in ref 38 and was
purified by flash chromatography with n-hexane−ethyl acetate (1:1) as
the eluent (yield 39%). 1H NMR (200 MHz, CDCl3): δ 2.84 (s, 3H),
3.25 (s, 3H), 7.31 (s, 1H), 7.55−7.62 (m, 1H), 7.73−7.80 (m, 2H),
8.06 (d. J = 8.3, 1H). MS (ESI) m/z calcd for C12H11ClN2ONa [M +
Na]+, 257.0; found, 257.2.
N-Butyl-2-chloro-N-methylquinoline-4-carboxamide (12). This
compound was prepared from of 2-hydroxy-4-quinolinecarboxylic
acid and N-methylbutylamine by following the procedure described in
ref 38 and was purified by flash chromatography with n-hexane−ethyl
acetate (9:1) as the eluent (yield 81%, mp 86−87 °C). Because the
amide nitrogen of this compound bears two different substituents, its
1H NMR spectrum shows the presence of two different rotamers in
equilibrium; for the sake of simplification, the integral intensities have
not been given. 1H NMR (200 MHz, CDCl3): δ 0.70 (t, J = 7.2),
0.98−1.17 (m), 1.37−1.55 (m), 1.65−1.79 (m), 2.78 (s), 3.04 (t, J =
7.5), 3.19 (s), 3.64 (t, J = 7.5), 7.28 (s), 7.53−7.61 (m), 7.71−7.78
(m), 8.04 (d. J = 8.2). MS (ESI) m/z calcd for C15H18ClN2O [M +
H]+, 277.1; found, 277.5.
tert-Butyl 2-Chloro-3-methylquinoline-4-carboxylate (16). A
solution of acid chloride 2538 (3.5 g, 14.6 mmol) in dry THF (15
mL) was cooled at 0−5 °C, and a mixture of potassium tert-butoxide
(1.64 g, 14.6 mmol) in 15 mL of dry THF was added. The resulting
mixture was stirred at the same temperature for 10 min and at room
temperature for 30 min. The reaction mixture was then poured onto
crushed ice, and the precipitate was collected by filtration, dried under
reduced pressure, and purified by flash chromatography with
petroleum ether−ethyl acetate (9:1) as the eluent to obtain 16 as a
white solid (3.4 g, yield 84%). An analytical sample was obtained by
recrystallization from n-hexane (mp 107−108 °C). 1H NMR (400
MHz, CDCl3): δ 1.69 (s, 9H), 2.52 (s, 3H), 7.56 (t, J = 7.6, 1H);
7.67−7.74 (m, 2H), 7.99 (d, J = 8.4, 1H). MS (ESI) m/z calcd for
C15H17ClNO2 [M + H]
+, 278.1; found, 278.0.
2-Chloro-N,N-dipropylquinoline-6-fluoro-4-carboxamide (22). A
mixture of acid 27a (1.0 g, 4.43 mmol) in thionyl chloride (5.0 mL)
was refluxed under argon for 2 h. The thionyl chloride excess was then
removed under reduced pressure, and the resulting acid chloride was
immediately used without further purification. To a mixture of acid
chloride in 20 mL of dichloromethane cooled at 0−5 °C,
dipropylamine (0.57 mL, 4.16 mmol) and triethylamine (TEA, 1.0
mL) were added and the resulting mixture was stirred at room
temperature for 30 min while the reaction progress was monitored by
TLC. The reaction mixture was concentrated under reduced pressure
and partitioned between CH2Cl2 and water. The organic layer was
dried over sodium sulfate and concentrated under reduced pressure.
The resulting residue was purified by flash chromatography with n-
hexane−ethyl acetate (8:2) as the eluent to obtain 22 as pale-yellow
oil, which slowly crystallized on standing (1.1 g, yield 86%). 1H NMR
(200 MHz, CDCl3): δ 0.67 (t, J = 7.3, 3H), 1.02 (t, J = 7.3, 3H), 1.37−
1.56 (m, 2H), 1.67−1.86 (m, 2H), 2.99 (t, J = 7.3, 2H), 3.54 (br s,
2H), 7.26−7.37 (m, 2H), 7.45−7.55 (m, 1H), 7.98−8.05 (m, 1H). MS
(ESI) m/z calcd for C16H19ClFN2O [M + H]
+, 309.1; found, 309.6.
N-Benzyl-2-chloro-6-fluoro-N-methylquinoline-4-carboxamide
(23). A mixture of acid 27a (1.0 g, 4.43 mmol) in thionyl chloride (5.0
mL) was refluxed under argon for 2 h. The thionyl chloride excess was
then removed under reduced pressure, and the resulting acid chloride
was immediately used without further purification. To a mixture of
acid chloride in 20 mL of dichloromethane cooled at 0−5 °C, N-
methylbenzylamine (0.53 mL, 4.11 mmol) and TEA (1.0 mL) were
added and the resulting mixture was stirred at room temperature for
30 min while the reaction progress was monitored by TLC. The
reaction mixture was concentrated under reduced pressure and
partitioned between CH2Cl2 and water. The organic layer was dried
over sodium sulfate and concentrated under reduced pressure. The
resulting residue was purified by flash chromatography with n-hexane−
ethyl acetate (7:3) as the eluent to obtain 23 as pale-yellow oil, which
slowly crystallized on standing (1.1 g, yield 81%, mp 97−98 °C).
Because the amide nitrogen of this compound bears two different
substituents, its 1H NMR spectrum shows the presence of two
different rotamers in equilibrium; for the sake of simplification, the
integral intensities have not been given. 1H NMR (200 MHz, CDCl3):
δ 2.69 (s), 3.12 (s), 4.28 (s), 4.80 (s), 6.98−7.01 (m), 7.23−7.50 (m),
7.94−8.01 (m). MS (ESI) m/z calcd for C18H15ClFN2O [M + H]+,
329.1; found, 329.3.
N-Benzyl-6-bromo-2-chloro-N-methylquinoline-4-carboxamide
(24). A mixture of acid 27b (1.3 g, 4.54 mmol) in dichloromethane (20
mL) and thionyl chloride (5.0 mL) was refluxed under argon for 3 h.
The volatile was then removed under reduced pressure, and the
resulting acid chloride was immediately used without further
purification. To a mixture of acid chloride in 20 mL of dichloro-
methane cooled at 0−5 °C, N-methylbenzylamine (1.2 mL, 9.3 mmol)
and TEA (1.0 mL) were added, and the resulting mixture was stirred at
room temperature for 30 min while the reaction progress was
monitored by TLC. The reaction mixture was washed with water,
dried over sodium sulfate, and concentrated under reduced pressure.
The resulting residue was purified by flash chromatography with n-
hexane−ethyl acetate (7:3) as the eluent to obtain 24 as a white solid
(1.0 g, yield 57%, mp 127−128 °C). Because the amide nitrogen of
this compound bears two different substituents, its 1H NMR spectrum
shows the presence of two different rotamers in equilibrium; for the
sake of simplification, the integral values have not been given. 1H
NMR (200 MHz, CDCl3): δ 2.73 (s), 3.19 (s), 4.31 (s), 4.86 (s),
7.02−7.06 (m), 7.29−7.45 (m), 7.78−7.97 (m). MS (ESI) m/z calcd
for C18H15BrClN2O [M + H]
+, 389.0; found, 389.4.
2-Chloro-6-fluoro-4-quinolinecarboxylic Acid (27a). A mixture of
6-fluoro-2-hydroxy-4-quinolinecarboxylic acid (26a,41 3.0 g, 14.5
mmol) in 15 mL of POCl3 was heated to reflux for 2 h and then
poured onto crushed ice. The precipitate was extracted with
chloroform, and the organic layer was dried over sodium sulfate and
concentrated under reduced pressure. Purification of the residue by
washing with n-hexane gave acid 27a (2.3 g, yield 70%), which was
promptly used in the subsequent step. 1H NMR (200 MHz, DMSO-
d6): δ 7.75−7.85 (m, 1H), 7.97 (s, 1H), 8.06−8.14 (m, 1H), 8.39−
8.46 (m, 1H), 14.20 (br s, 1H).
6-Bromo-2-chloro-4-quinolinecarboxylic Acid (27b). A mixture of
6-bromo-2-hydroxy-4-quinolinecarboxylic acid (26b) (1.0 g, 3.7
mmol) in 10 mL of POCl3 was heated to reflux for 3 h and then
poured onto crushed ice. The precipitate was extracted with ethyl
acetate, and the organic layer was dried over sodium sulfated and
concentrated under reduced pressure. Purification of the residue by
washing with n-hexane gave acid 27b (1.0 g, yield 94%), which was
promptly used in the subsequent step. 1H NMR (200 MHz, DMSO-
d6): δ 7.95 (m, 3H), 8.89 (s, 1H). MS (ESI, negative ions) m/z calcd
for C10H4BrClNO2 [M − H+]−, 283.9; found, 284.1.
5-Phenylimidazo[1,5-a]quinoline-3-carboxylic Acid (32). A mix-
ture of 8b (1.0 g, 2.90 mmol) in formic acid (10 mL) was stirred at
room temperature overnight and then concentrated under reduced
pressure to obtain acid 32 as an off-white solid (0.75 g, yield 90%, mp
264−265 °C). 1H NMR (200 MHz, DMSO-d6): δ 7.45−7.81 (m,
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9H), 8.58 (d, J = 8.2, 1H), 9.25 (s, 1H) 12.59 (br s, 1H). MS (ESI) m/
z calcd for C18H13N2O2 [M + H]
+, 289.1; found, 289.2.
4-Methyl-5-phenylimidazo[1,5-a]quinoline-3-carboxylic Acid
(33). A mixture of 8e (0.20 g, 0.558 mmol) in formic acid (10 mL)
was stirred at room temperature overnight and then concentrated
under reduced pressure to obtain acid 33 (0.15 g, yield 89%), which
was used in the subsequent step without further purification.
2-Chloro-3-hydroxymethyl-4-phenylquinoline (34). To a 1 M
solution of lithium aluminum hydride (LAH, 20 mL, 20 mmol) cooled
at 0−5 °C, a solution of 3062 (3.0 g, 9.62 mmol) in THF (40 mL) was
added and the resulting mixture was stirred at the same temperature
for 15 min. The LAH excess was then decomposed with water, and the
reaction mixture was filtered and concentrated under reduced pressure.
The residue was partitioned between dichloromethane and water, and
the organic layer was washed with brine, dried over sodium sulfate, and
concentrated under reduced pressure. Purification of the residue by
flash chromatography with n-hexane−ethyl acetate (1:1) as the eluent
afforded 34 (1.21 g, yield 47%), which was used in the subsequent step
without further purification. 1H NMR (200 MHz, CDCl3): δ 2.30 (t, J
= 6.6, 1H), 4.64 (d, J = 6.2, 2H), 7.29−7.75 (m, 8H), 8.02 (d, J = 8.3,
1H).
3-[(tert-Butyldimethylsilyloxy)methyl]-2-chloro-4-phenylquino-
line (35). To a solution of 34 (1.2 g, 4.45 mmol) in dichloromethane
(40 mL) containing imidazole (0.385 g, 5.66 mmol) and cooled at 0−
5 °C, tert-butyldimethylsilyl chloride (0.77 g, 5.1 mmol) was added.
The resulting mixture was stirred at the same temperature for 15 min
and then at room temperature for 2.5 h. The reaction mixture was
partitioned between dichloromethane and water, and the organic layer
was washed with brine, dried over sodium sulfate, and concentrated
under reduced pressure to afford 35 (1.4 g, yield 82%), which was used
in the subsequent step without further purification. 1H NMR (200
MHz, CDCl3): δ 0.00 (s, 6H), 0.85 (s, 9H), 4.59 (s, 2H), 7.32−7.72
(m, 8H), 8.02 (d, J = 8.4, 1H). MS (ESI) m/z calcd for C22H27ClNOSi
[M + H]+, 384.2; found, 384.0.
Ethyl 4-[(tert-Butyldimethylsilyloxy)methyl]-5-phenylimidazo[1,5-
a]quinoline-3-carboxylate (36). This compound was prepared from
35 (1.38 g, 3.59 mmol), ethyl isocyanoacetate (1.3 mL, 11.9 mmol),
and potassium tert-butoxide (1.2 g, 10.7 mmol) according to the
general procedure for the synthesis of 7a−i,k−m,o−y to obtain pure
36 as a brown solid (1.35 g, yield 82%), which was used in the
subsequent step without further purification. 1H NMR (200 MHz,
CDCl3): δ −0.17 (s, 6H), 0.71 (s, 9H), 1.45 (t, J = 7.0, 3H), 4.43 (q, J
= 7.0, 2H), 5.00 (s, 2H), 7.23−7.63 (m, 8H), 8.06 (d, J = 8.2, 1H),
8.70 (s, 1H). MS (ESI) m/z calcd for C27H33N2O3Si [M + H]
+, 461.2;
found, 460.8.
X-ray Crystallography. Single crystals of compounds 7p,s,t and
10a−c were submitted to X-ray data collection on an Oxford-
Diffraction Xcalibur Sapphire 3 diffractometer with a graphite
monochromated Mo Kα radiation (λ = 0.71073 Å) at 293 K. The
structures were solved by direct methods implemented in SHELXS-97
program.63 The refinements were carried out by full-matrix anisotropic
least-squares on F2 for all reflections for non-H atoms by means of the
SHELXL-97 program.64 Crystallographic data (excluding structure
factors) concerning the structures solved in this paper have been
deposited with the Cambridge Crystallographic Data Centre as
supplementary publication nos. CCDC 1437490 (7p), 1437488
(7s), 1437489 (7t), 1437487 (10a), 1437486 (10b), and 1446645
(10c). Copies of the data can be obtained, free of charge, on
application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK;
(fax: + 44 (0) 1223 336 033; or e-mail: deposit@ccdc.cam.ac.uk).
Radioligand Binding Studies in Native Bovine and Human
Cerebral Receptors. [3H]Flumazenil (specific activity 70.8 Ci/
mmol) was obtained from PerkinElmer Life Science (Milano, Italy).
All other chemicals were at reagent grade and were obtained from
commercial suppliers.
Bovine cortex was obtained from the local slaughterhouse. Human
cortex samples were taken post-mortem at the Department of
Pathological Anatomy, University of Pisa, during autopsy sessions.
The subjects had died from causes not primarily involving the brain
and had not suffered from any psychiatric or neurological disorders.
The time between death and tissue dissection/freezing ranged from 18
to 36 h. The samples were immediately packed in dry ice and stored in
a −80° freezer. The study was approved by the Ethics Committee of
the University of Pisa, Italy.
Bovine and human cerebral cortex membranes were prepared in
agreement with Martini et al.65 Briefly, cerebral cortex was
homogenized in 10 volumes of ice cold 0.32 M sucrose containing
protease inhibitors. The homogenate was centrifuged at 1000g for 10
min at 4 °C, the resulting pellet was discarded, and the supernatant
was recentrifuged at 48000g for 15 min at 4 °C. Then the pellet was
osmotically shocked by suspension in 10 volumes of 50 mM Tris-
citrate buffer at pH 7.4 containing protease inhibitors and
recentrifuged at 48000g for 15 min at 4 °C. The resulting membranes
were frozen and washed by means of the procedure previously
described for removing endogenous GABA from cerebral cortex.66
Finally, the pellet was suspended in 10 volumes of 50 mM Tris-citrate
buffer pH 7.4 and used in the binding assay. Protein concentration was
assayed by the method of Lowry et al.67 by means of bovine serum
albumin as the standard.
[3H]Flumazenil binding studies were performed as previously
reported.68 The [3H]flumazenil binding was performed in triplicate by
incubating aliquots of the membrane fractions (0.2−0.3 mg of protein)
at 0 °C for 90 min in 0.5 mL of 50 mM Tris-citrate buffer, pH 7.4, with
approximately 0.2 nM [3H]flumazenil. Nonspecific binding was
defined in the presence of 10 μM diazepam. After incubation, the
samples were diluted at 0 °C with 5 mL of the assay buffer and
immediately harvested onto GF/B filters (Brandel) by means of a
harvester and washed with ice-cold assay buffer. The filters were
washed twice with 5 mL of the buffer, dried, and 4 mL of Ready
Protein Beckman scintillation cocktail added; radioactivity was
counted in a Packard LS 1600 liquid-phase scintillation β counter.
The compounds were routinely dissolved into DMSO and added to
the assay mixture to amount to a final volume of 0.5 mL. Blank
experiments were carried out to determine the effect of the solvent
(2%) on binding. At least six different concentrations spanning 3
orders of magnitude, adjusted approximately for the IC50 of each
compound, were used. IC50 values were calculated by a nonlinear
formula on a computer program (GraphPad, San Diego, CA) and
converted into the corresponding Ki values by the Cheng and Prusoff
equation with the Kd values of the radioligand in these different tissues
already known.69 The Kd of [
3H]flumazenil binding to cortex
membrane from bovine and human was 0.85 and 0.91 nM,
respectively. The GABA ratio was determined by calculating Ki
without GABA/Ki with GABA 50 μM for each compound.
In Vitro Efficacy in 36Cl− Uptake Assay in Rat Cerebrocortical
Synaptoneurosomes. 36Cl− (specific activity 9.69 μCi/g) was
obtained from PerkinElmer Life Science (Milan, Italy). All other
chemicals were reagent grade and were obtained from commercial
suppliers.
The 36Cl− uptake was measured in rat cerebrocortical synaptoneur-
osomes as described by Schwartz et al.,48 with minor modifications.
Briefly, the cerebral cortex was dissected from Sprague−Dawley male
rats suspended 1:10 with ice-cold solution containing 145 mM NaCl, 5
mM KCl, 5 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, pH 7 (T1
buffer), and 10 mM D-glucose; they were homogenized with a glass−
glass homogenizer (five strokes) and filtered through three layers of
nylon mesh (160 μm) and a 10 μm Millipore filter. The filtrates were
centrifuged at 1000g for 15 min. After discarding the supernatant, the
pellet was gently resuspended in T1 buffer and washed once more by
centrifugation (1000g for 15 min). The final pellet containing the
synaptoneurosomes was suspended 1:2 in T1 buffer and kept on ice
until ready for assay (no longer than 30 min).
Aliquots of synaptoneurosome suspensions (1.5−2 mg of protein)
were preincubated at 30 °C for 10 min prior to the addition of 0.2 μCi
of 36Cl−. Drugs were added simultaneously with the 36Cl− (0.35 mL
total assay volume). 36Cl− uptake was stopped 10 s later by the
addition of 5 mL of ice-cold HEPES, followed by vacuum filtration
through glass fiber filters (Whatman GF/B) that had been soaked with
0.05% polyethylenimine to reduce nonspecific binding of 36Cl−. The
filters were washed three more times with 5 mL of ice-cold buffer and
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placed into scintillation vials containing 4 mL of Ready Protein
Beckman scintillation cocktail, and radioactivity was counted in a
Packard LS 1600 liquid-phase scintillation β counter. Data are
expressed as percent stimulation of 36Cl− uptake above basal level.
In Vitro Efficacy in Excitotoxic-Mediated Injury. Compounds.
Trizma base, ascorbic acid, sodium pyruvate, sodium EGTA, β-
nicotinamide adenine dinucleotide (NAD+), β-nicotinamide adenine
dinucleotide reduced form (NADH), and all artificial cerebrospinal
fluid (ACSF) components were purchased from Sigma-Aldrich Co. (St
Louis, MO, U.S.A.). Drugs molecules were solubilized into DMSO and
diluted at the final desired concentration with ACSF immediately
before the experiment. Final DMSO concentration in the ACSF used
for the experiments was always lower than 0.1%, and this had no effect
per se on the biochemical parameters investigated.54,59 All other
materials were from standard local commercial sources and of the
highest grade available.
Animals. All animal care and experimental protocols were in strict
compliance with the European Union Guidelines for the Care and the
Use of Laboratory Animals (the European Union Directive 2010/63/
EU) and were approved by the Italian Department of Health (813/
2015-PR).
Sprague−Dawley male rats (300−350 g; Charles River Italia, Calco,
Italy) were kept in large cages under a 12:12 h day−night cycle at 20
°C ambient temperature. Drinking water and conventional laboratory
rat food were available ad libitum. Before sacrifice, animals were
anaesthetized by intraperitoneal injection of a mixture of Ketavet (30
mg/kg ketamine; Gellini, Aprilia, Italy) and xylazine (8 mg/kg Xilor;
Bayer AG, Wuppertal, Germany).
Preparation of Slices. After the sacrifice of the animal (by
decapitation) the whole brain was rapidly removed, chilled to 4 °C by
immersion into cold ACSF (composition in mM: 120 NaCl, 2.5 KCl,
1.3 MgCl2, 1.0 NaH2PO4, 1.5 CaCl2, 26 NaHCO3, 11 glucose,
saturated with 95% O2−5% CO2, with a final pH of 7.4, osmolality
285−290 mOsmol). The cortex was dissected and cut into 400 μm
thick slices by using a manual chopper (Stoelting Co., Wood Dale, IL,
USA). Afterward, slices were maintained in oxygenated ACSF enriched
with 400 μM ascorbic acid for 1 h at room temperature to allow
maximal recovery from slicing trauma.59
In Vitro Ischemia-Like Conditions. Cortical slices from a single
brain were placed in covered incubation flasks containing ACSF (2
mL) continuously bubbled with a 95% O2−5% CO2 gas mixture and
incubated at 37 °C for an additional period of 30 min. Afterward,
OGD was carried out by incubating slices for 30 min into ACSF in
which glucose was replaced by an equimolar amount of sucrose and
continuously bubbled with a 95% N2−5% CO2 gas mixture. After the
OGD phase, the ischemic-like solution was replaced by fresh,
oxygenated ACSF for an additional 90 min period (reoxygenation
phase). The protective effect of the tested compounds was investigated
by adding them to ACSF during the entire reoxygenation phase.
Assessment of Tissue Injury. Cell damage was assessed by
measuring the amount of LDH released into the ACSF during the
entire reperfusion period.54,59 LDH activity was determined
spectrophotometrically via the rate of decrease in absorbance at 340
nm of NADH during its oxidation to NAD+ and the concomitant
reduction of pyruvate to lactate.
Data Analysis. Each experimental block was performed by using
brain slices derived from at least four rats. The data are reported as
mean ± SEM, and statistical analysis was performed by using one-way
ANOVA followed by Dunnet post-test (GraphPad Software, San
Diego, CA, USA). In all comparisons, the level of statistical
significance (P) was set at 0.05.
In Vivo Efficacy. The experiments were carried out in accordance
with the Animal Protection Law of the Republic of Italy, DL No. 116/
1992, based on the European Communities Council Directive of
November 24, 1986 (86/609/EEC). All efforts were made to
minimize animal suffering and to reduce the number of animals
involved. Male CD-1 albino mice (22−24 g) and male Swiss Webster
(20−26 g) (Morini, Italy) were used. Twelve mice were housed per
cage and fed a standard laboratory diet, with tap water ad libitum for
12 h/12 h light−dark cycles (lights on at 7:00). The cages were
brought into the experimental room the day before the experiment for
acclimatization purposes. All experiments were performed between
10:00 and 15:00.
Rota-rod Test. The integrity of the animals’ motor coordination was
assessed using a Rota-rod apparatus (Ugo Basile, Varese, Italy) at a
rotating speed of 16 rpm. The treatment was performed before the
test. The numbers of falls from the rod were counted for 30 s, 30 min
after drug administration, and the test was performed according to the
method described by Vaught et al.70
Light−Dark Box Test. The apparatus (50 cm long, 20 cm wide, and
20 cm high) consisted of two equal acrylic compartments, one dark
and one light, illuminated by a 60 W bulb lamp and separated by a
divider with a 10 cm × 3 cm opening at floor level. Each mouse was
tested by placing it in the center of the lighted area, away from the
dark one, and allowing it to explore the novel environment for 5 min.
The number of transfers from one compartment to the other and the
time spent in the illuminated side were measured. This test exploited
the conflict between the animal’s tendency to explore a new
environment and its fear of bright light.71
Passive-Avoidance Test. The test was performed according to the
step-through method described by Jarvik et al.72 The apparatus
consisted of a two-compartment acrylic box with a lighted compart-
ment connected to a darkened one by a guillotine door. As soon as the
mouse entered the dark compartment, it received a thermal shock
punishment. The latency times for entering the dark compartment
were measured in the training test and after 24 h in the retention test.
The maximum entry latency allowed in the training and retention
sessions was, respectively, 60 and 180 s.
Hole-Board Test. The hole-board test consisted of a 40 cm2 plane
with 16 flush-mounted cylindrical holes (3 cm diameter) distributed
four by four in an equidistant, grid-like manner. Mice were placed on
the center of the board one by one and allowed to move about freely
for a period of 5 min each. Two electric eyes, crossing the plane from
midpoint to midpoint of the opposite sides, thus dividing the plane
into four equal quadrants, automatically signaled the movement of the
animal (counts in 5 min) on the surface of the plane (spontaneous
motility). Miniature photoelectric cells in each of the 16 holes
recorded (counts in 5 min) the exploration of the holes (exploratory
activity) by the mice. A total of 12−15 mice per group were tested.73
Compound Administration. Diazepam (Valium 10, Roche) was
dissolved into isotonic (NaCl 0.9%) saline solution and injected
subcutaneously. The new compounds were administered by the po
route and were suspended in 1% carboxymethylcellulose sodium salt
and sonicated immediately before use. Drug concentrations were
prepared in such a way that the necessary dose could be administered
in a 10 mL/kg volume of carboxymethylcellulose 1% by the per os or
subcutaneous route.
Statistical Analysis. All experimental result are given as the mean ±
SEM. Each value represents the mean of 25 mice. An analysis of
variance, ANOVA, followed by Fisher’s protected least significant
difference procedure for post hoc comparison, were used to verify
significance between two means of behavioral results. The data were
analyzed with the StatView software for Macintosh (1992). P values of
less than 0.05 were considered significant.
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